+

WO2019006280A1 - Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation - Google Patents

Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation Download PDF

Info

Publication number
WO2019006280A1
WO2019006280A1 PCT/US2018/040257 US2018040257W WO2019006280A1 WO 2019006280 A1 WO2019006280 A1 WO 2019006280A1 US 2018040257 W US2018040257 W US 2018040257W WO 2019006280 A1 WO2019006280 A1 WO 2019006280A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
antigen
domain
binding fragment
Prior art date
Application number
PCT/US2018/040257
Other languages
English (en)
Inventor
Dimiter S. Dimitrov
Weizao Chen
Zhongyu Zhu
Rimas J. ORENTAS
Boro Dropulic
Dina SCHNEIDER
Original Assignee
Lentigen Technology, Inc.
The U.S.A., As Representated By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lentigen Technology, Inc., The U.S.A., As Representated By The Secretary, Department Of Health And Human Services filed Critical Lentigen Technology, Inc.
Priority to CA3066953A priority Critical patent/CA3066953A1/fr
Publication of WO2019006280A1 publication Critical patent/WO2019006280A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily

Definitions

  • This disclosure concerns CD33-specific monoclonal antibodies and conjugates thereof.
  • This disclosure further concerns use of the monoclonal antibodies and conjugates, such as for the diagnosis and treatment of CD33-positive cancers.
  • CD33 is a transmembrane receptor expressed on cells of myeloid lineage, and some lymphoid cells.
  • CD33 which is also known as Siglec-3 (sialic acid binding Ig-like lectin 3), binds sialic acids and is a member of the SIGLEC family of lectins.
  • the extracellular portion of CD33 includes two immunoglobulin domains (an IgV domain and an IgC2 domain), while the intracellular portion contains immunoreceptor tyrosine-based inhibitor motifs (ITIMs) that are implicated in inhibition of cellular activity.
  • ITIMs immunoreceptor tyrosine-based inhibitor motifs
  • AML Acute myeloid leukemia
  • ml 033-9 binds to soluble recombinant CD33 and cell- surface CD33 with high affinity.
  • ml 033-10 binds to soluble recombinant CD33 and cell- surface CD33 with high affinity.
  • ml 033-15 binds to soluble recombinant CD33 and cell- surface CD33 with high affinity.
  • the monoclonal antibodies that bind, such as specifically bind, CD33.
  • the monoclonal antibodies include one or more complementarity determining region (CDR) sequences of ml033-9, ml033-10, ml 033-12, ml 033-15, ml 033-2 or ml 033-4.
  • conjugates that include a disclosed CD33-specific monoclonal antibody or antigen-binding fragment thereof.
  • Compositions that include a CD33-specific monoclonal antibody or antigen-binding fragment and a pharmaceutically acceptable carrier are also provided by the present disclosure.
  • Methods of treating a CD33-positive cancer in a subject, and methods of inhibiting metastasis of a CD33-positive cancer in a subject are also provided.
  • the methods include administering to the subject a monoclonal antibody or antigen-binding fragment disclosed herein, or administering to the subject an immunoconjugate, ADC, multi-specific antibody, antibody-nanoparticle conjugate or fusion protein comprising a monoclonal antibody (or antigen-binding fragment) disclosed herein.
  • the method includes contacting the sample with a monoclonal antibody or antigen-binding fragment disclosed herein, and detecting binding of the antibody to the sample. Also provided are methods of diagnosing a subject as having a CD33-positive cancer. In some embodiments, the method includes contacting a sample from the subject with a CD33-specific monoclonal antibody antigen-binding fragment disclosed herein, and detecting binding of the antibody to the sample.
  • FIG. 1 is a graph showing binding of ml033-9 scFv to human recombinant CD33, as measured by ELISA.
  • FIGS. 2A-2C are FACS plots showing binding of ml 033-9 scFv to CD33-negative ALL cell line RS4;11 (FIG. 2A), CD33-positive AML cell line MV4-11 (FIG. 2B) and CD33-negative Jurkat T cells (FIG. 2C).
  • FIG. 3 is a graph showing binding of ml033-10 scFv to human recombinant CD33, as measured by ELISA.
  • FIGS. 4A-4C are FACS plots showing binding of ml 033-10 scFv to CD33-negative ALL cell line RS4;11 (FIG. 4A), CD33-positive AML cell line MV4-11 (FIG. 4B) and CD33- negative Jurkat T cells (FIG. 4C).
  • FIG. 5 is a graph showing binding of ml033-12 scFv to human recombinant CD33, as measured by ELISA.
  • FIGS. 6A-6C are FACS plots showing binding of ml 033-12 scFv to CD33-negative ALL cell line RS4;11 (FIG. 6A), CD33-positive AML cell line MV4-11 (FIG. 6B) and CD33- negative Jurkat T cells (FIG. 6C).
  • FIG. 7 is a graph showing binding of ml033-15 scFv to human recombinant CD33, as measured by ELISA.
  • FIGS. 8A-8C are FACS plots showing binding of ml 033-15 scFv to CD33-negative ALL cell line RS4;11 (FIG. 8A), CD33-positive AML cell line MV4-11 (FIG. 8B) and CD33- negative Jurkat T cells (FIG. 8C).
  • FIG. 9 is a graph showing binding of ml033-2 VH domain antibody to human recombinant CD33, as measured by ELISA.
  • FIGS. lOA-lOC are FACS plots showing binding of ml 033-2 VH domain antibody to CD33-negative ALL cell line RS4;11 (FIG. 10A), CD33-positive AML cell line MV4-11 (FIG. 10B) and CD33-negative 293T cells (FIG. IOC).
  • FIG. 11 is a graph showing binding of ml033-4 VH domain antibody to human recombinant CD33, as measured by ELISA.
  • FIGS. 12A-12C are FACS plots showing binding of ml 033-2 VH domain antibody to CD33-negative ALL cell line RS4;11 (FIG. 12A), CD33-positive AML cell line MV4-11 (FIG. 12B) and CD33-negative CHO cells (FIG. 12C).
  • nucleic and amino acid sequences listed in the accompanying sequence listing are shown using standard letter abbreviations for nucleotide bases, and three letter code for amino acids, as defined in 37 C.F.R. 1.822. Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included by any reference to the displayed strand.
  • SEQ ID NO: 1 is a nucleic acid sequence encoding the ml 033-9 VH domain.
  • SEQ ID NO: 2 is the amino acid sequence of the ml 033-9 VH domain.
  • SEQ ID NO: 3 is a nucleic acid sequence encoding the ml 033-9 VL domain.
  • SEQ ID NO: 4 is the amino acid sequence of the ml 033-9 VH domain.
  • SEQ ID NO: 5 is a nucleic acid sequence encoding the ml033-10 VH domain.
  • SEQ ID NO: 6 is the amino acid sequence of the ml 033- 10 VH domain.
  • SEQ ID NO: 7 is a nucleic acid sequence encoding the ml 033-10 VL domain.
  • SEQ ID NO: 8 is the amino acid sequence of the ml 033- 10 VH domain.
  • SEQ ID NO: 9 is a nucleic acid sequence encoding the ml033-12 VH domain.
  • SEQ ID NO: 10 is the amino acid sequence of the ml033-12 VH domain.
  • SEQ ID NO: 11 is a nucleic acid sequence encoding the ml033-12 VL domain.
  • SEQ ID NO: 12 is the amino acid sequence of the ml033-12 VH domain.
  • SEQ ID NO: 13 is a nucleic acid sequence encoding the ml033-15 VH domain.
  • SEQ ID NO: 14 is the amino acid sequence of the ml033-15 VH domain.
  • SEQ ID NO: 15 is a nucleic acid sequence encoding the ml033-15 VL domain.
  • SEQ ID NO: 16 is the amino acid sequence of the ml033-15 VH domain.
  • SEQ ID NO: 17 is a nucleic acid sequence encoding single domain antibody ml 033-2.
  • SEQ ID NO: 18 is the amino acid sequence of single domain antibody ml 033-2.
  • SEQ ID NO: 19 is a nucleic acid sequence encoding single domain antibody ml 033-4.
  • SEQ ID NO: 20 is the amino acid sequence of single domain antibody ml 033-4.
  • AML Acute myeloid leukemia
  • AML An aggressive form of leukemia characterized by the overproduction of myeloblasts.
  • AML is also known as acute myeloblastic leukemia, acute myelogenous leukemia and acute nonlymphocytic leukemia (ANLL).
  • Antibody A polypeptide ligand comprising at least one variable region that recognizes and binds (such as specifically recognizes and specifically binds) an epitope of an antigen.
  • Mammalian immunoglobulin molecules are composed of a heavy (H) chain and a light (L) chain, each of which has a variable region, termed the variable heavy (VH) region and the variable light (VL) region, respectively. Together, the VH region and the VL region are responsible for binding the antigen recognized by the antibody.
  • VH variable heavy
  • VL variable light
  • Antibody isotypes not found in mammals include IgX, IgY, IgW and IgNAR.
  • IgY is the primary antibody produced by birds and reptiles, and has some functionally similar to mammalian IgG and IgE.
  • IgW and IgNAR antibodies are produced by cartilaginous fish, while IgX antibodies are found in amphibians.
  • Antibody variable regions contain "framework” regions and hypervariable regions, known as “complementarity determining regions” or “CDRs.”
  • the CDRs are primarily responsible for binding to an epitope of an antigen.
  • the framework regions of an antibody serve to position and align the CDRs in three-dimensional space.
  • the amino acid sequence boundaries of a given CDR can be readily determined using any of a number of well-known numbering schemes, including those described by Kabat et al. ⁇ Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services, 1991 ; the "Kabat” numbering scheme), Chothia et al.
  • single-domain antibody refers to an antibody having a single domain (a variable domain) that is capable of specifically binding an antigen, or an epitope of an antigen, in the absence of an additional antibody domain.
  • Single-domain antibodies include, for example, VH domain antibodies, VNAR antibodies, camelid VHH antibodies, and VL domain antibodies.
  • VNAR antibodies are produced by cartilaginous fish, such as nurse sharks, wobbegong sharks, spiny dogfish and bamboo sharks.
  • Camelid VHH antibodies are produced by several species including camel, llama, alpaca, dromedary, and guanaco, which produce heavy chain antibodies that are naturally devoid of light chains.
  • a “monoclonal antibody” is an antibody produced by a single clone of lymphocytes or by a cell into which the coding sequence of a single antibody has been transfected. Monoclonal antibodies are produced by methods known to those of skill in the art. Monoclonal antibodies include humanized monoclonal antibodies.
  • a “chimeric antibody” has framework residues from one species, such as human, and CDRs (which generally confer antigen binding) from another species.
  • a “humanized” antibody is an immunoglobulin including a human framework region and one or more CDRs from a non-human (for example a mouse, rabbit, rat, shark or synthetic) immunoglobulin.
  • the non-human immunoglobulin providing the CDRs is termed a "donor,” and the human immunoglobulin providing the framework is termed an "acceptor.”
  • all CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, i.e., at least about 85-90%, such as about 95% or more identical.
  • a humanized immunoglobulin all parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences.
  • a humanized antibody binds to the same antigen as the donor antibody that provides the CDRs.
  • Humanized or other monoclonal antibodies can have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions.
  • ADC Antibody-drug conjugate
  • ADC A molecule that includes an antibody (or antigen- binding fragment of an antibody) conjugated to a drug, such as a cytotoxic agent.
  • ADCs can be used to specifically target a drug to cancer cells through specific binding of the antibody to a tumor antigen expressed on the cell surface.
  • exemplary drugs for use with ADCs include anti- microtubule agents (such as maytansinoids, auristatin E and auristatin F) and interstrand crosslinking agents (e.g. , pyrrolobenzodiazepines; PDBs).
  • Anti-microtubule agent A type of drug that blocks cell growth by stopping mitosis.
  • Anti-microtubule agents also referred to as “anti-mitotic agents,” are used to treat cancer.
  • Binding affinity Affinity of an antibody for an antigen.
  • affinity is calculated by a modification of the Scatchard method described by Frankel et al. , Mol. Immunol. , 16: 101-106, 1979.
  • binding affinity is measured by an antigen/antibody dissociation rate.
  • a high binding affinity is measured by a competition radioimmunoassay.
  • binding affinity is measured by ELISA.
  • antibody affinity is measured by flow cytometry.
  • An antibody that "specifically binds" an antigen is an antibody that binds the antigen with high affinity and does not significantly bind other unrelated antigens.
  • Bispecific antibody A recombinant protein that includes antigen-binding fragments of two different monoclonal antibodies, and is thereby capable of binding two different antigens.
  • bispecific antibodies are used for cancer immunotherapy by simultaneously targeting, for example, both CTLs (such as a CTL receptor component such as CD3) or effector natural killer (NK) cells, and a tumor antigen.
  • CTLs such as a CTL receptor component such as CD3
  • NK effector natural killer
  • a multi-specific antibody is a recombinant protein that includes antigen-binding fragments of at least two different monoclonal antibodies, such as two, three or four different monoclonal antibodies.
  • CD33 A transmembrane receptor expressed primarily by myeloid cells, but also by some lymphoid cells.
  • CD33 which is also known as Siglec-3 (sialic acid binding Ig-like lectin 3), binds sialic acids and is a member of the SIGLEC family of lectins.
  • CD33-positive cancer A cancer in which the cells express higher levels of CD33 than a control, such as non-cancer cells or a reference value. Expression of CD33 can be detected using, for example, any immunoassay known in the art, such as by ELISA, FACS, Western blot or immunohistochemistry of tumor cells.
  • a CD33-expressing cancer can also be identified by diagnosing a subject with a particular type of cancer that is known to express CD33, such as AML, a lymphoma or a squamous cell carcinoma.
  • Chemotherapeutic agent Any chemical agent with therapeutic usefulness in the treatment of diseases characterized by abnormal cell growth. Such diseases include tumors, neoplasms, and cancer as well as diseases characterized by hyperplastic growth such as psoriasis.
  • a chemotherapeutic agent is an agent of use in treating AML.
  • a chemotherapeutic agent is a radioactive compound.
  • One of skill in the art can readily identify a chemotherapeutic agent of use (see for example, Slapak and Kufe, Principles of Cancer Therapy, Chapter 86 in Harrison's Principles of Internal Medicine, 14th edition; Perry et al , Chemotherapy, Ch.
  • Combination chemotherapy is the administration of more than one agent to treat cancer.
  • One example is the administration of an antibody that binds CD33 used in combination with a radioactive or chemical compound.
  • CDR Complementarity determining region
  • a "conjugate” is an antibody or antibody fragment (such as an antigen-binding fragment) covalently linked to an effector molecule or a second protein (such as a second antibody).
  • the effector molecule can be, for example, a drug, toxin, therapeutic agent, detectable label, protein, nucleic acid, lipid, nanoparticle, carbohydrate or recombinant virus.
  • An antibody conjugate is often referred to as an "immunoconjugate.”
  • the conjugate comprises an antibody linked to a drug (e.g.
  • antibody-drug conjugate a cytotoxic agent
  • ADC antibody-drug conjugate
  • Other antibody conjugates include, for example, multi-specific (such as bispecific or trispecific) antibodies and chimeric antigen receptors (CARs).
  • Conservative variant “Conservative” amino acid substitutions are those substitutions that do not substantially affect or decrease the affinity of a protein, such as an antibody to CD33.
  • a monoclonal antibody that specifically binds CD33 can include at most about 1, at most about 2, at most about 5, and most about 10, or at most about 15 conservative substitutions and specifically bind the CD33 polypeptide.
  • the term "conservative variant” also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid, provided that antibody specifically binds CD33.
  • Non-conservative substitutions are those that reduce an activity or binding to CD33.
  • Conservative amino acid substitution tables providing functionally similar amino acids are well known to one of ordinary skill in the art. The following six groups are examples of amino acids that are considered to be conservative substitutions for one another:
  • Placement in direct physical association includes both in solid and liquid form.
  • Cytotoxic agent Any drug or compound that kills cells.
  • Cytotoxicity The toxicity of a molecule, such as an immunotoxin, to the cells intended to be targeted, as opposed to the cells of the rest of an organism.
  • toxicity refers to toxicity of an immunotoxin to cells other than those that are the cells intended to be targeted by the targeting moiety of the immunotoxin
  • animal toxicity refers to toxicity of the immunotoxin to an animal by toxicity of the immunotoxin to cells other than those intended to be targeted by the immunotoxin.
  • Degenerate variant refers to a polynucleotide encoding a CD33 polypeptide or an antibody that binds CD33 that includes a sequence that is degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included as long as the amino acid sequence of the CD33 polypeptide or antibody that binds CD33 encoded by the nucleotide sequence is unchanged.
  • Diagnostic Identifying the presence or nature of a pathologic condition, such as cancer. Diagnostic methods differ in their sensitivity and specificity.
  • the "sensitivity” of a diagnostic assay is the percentage of diseased individuals who test positive (percent of true positives).
  • the "specificity” of a diagnostic assay is one minus the false positive rate, where the false positive rate is defined as the proportion of those without the disease who test positive. While a particular diagnostic method may not provide a definitive diagnosis of a condition, it suffices if the method provides a positive indication that aids in diagnosis.
  • “Prognostic” is the probability of development (e.g. , severity) of a pathologic condition, such as AML, a lymphoma or a squamous cell carcinoma.
  • Drug Any compound used to treat, ameliorate or prevent a disease or condition in a subject.
  • the drug is an anti-cancer agent, for example a cytotoxic agent, such as an anti-mitotic or anti-microtubule agent.
  • Effector molecule The portion of a chimeric molecule that is intended to have a desired effect on a cell to which the chimeric molecule is targeted. Effector molecule is also known as an effector moiety (EM), therapeutic agent, or diagnostic agent, or similar terms.
  • Therapeutic agents include such compounds as nucleic acids, proteins, peptides, amino acids or derivatives, glycoproteins, radioisotopes, lipids, carbohydrates, or recombinant viruses.
  • Nucleic acid therapeutic and diagnostic moieties include antisense nucleic acids, derivatized
  • the molecule linked to a targeting moiety may be an encapsulation system, such as a liposome or micelle that contains a therapeutic composition such as a drug, a nucleic acid (such as an antisense nucleic acid), or another therapeutic moiety that can be shielded from direct exposure to the circulatory system.
  • a targeting moiety such as an anti-CD33 antibody
  • a therapeutic composition such as a drug, a nucleic acid (such as an antisense nucleic acid), or another therapeutic moiety that can be shielded from direct exposure to the circulatory system.
  • Means of preparing liposomes attached to antibodies are well known to those of skill in the art (see, for example, U.S. Patent No. 4,957,735; and Connor et al. , Pharm Ther 28:341-365, 1985).
  • Diagnostic agents or moieties include radioisotopes and other detectable labels.
  • Detectable labels useful for such purposes are also well known in the art, and include radioactive isotopes such as 35 S, n C, 13 N, 15 0, 18 F, 19 F, 99m Tc, m I, 3 ⁇ 4, 14 C, 15 N, 90 Y, "Tc, m In and 125 I, fluorophores, chemiluminescent agents, and enzymes.
  • Epitope An antigenic determinant. These are particular chemical groups or peptide sequences on a molecule that are antigenic, i.e. that elicit a specific immune response. An antibody specifically binds a particular antigenic epitope on a polypeptide, such as CD33.
  • Framework region Amino acid sequences interposed between CDRs. Framework regions include variable light and variable heavy framework regions. The framework regions serve to hold the CDRs in an appropriate orientation for antigen binding.
  • Fusion protein A protein comprising at least a portion of two different (heterologous) proteins.
  • Heterologous Originating from a separate genetic source or species.
  • Immune response A response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus.
  • the response is specific for a particular antigen (an "antigen-specific response").
  • an immune response is a T cell response, such as a CD4 + response or a CD8 + response.
  • the response is a B cell response, and results in the production of specific antibodies.
  • Immunoconjugate A covalent linkage of an effector molecule to an antibody or functional fragment thereof.
  • the effector molecule can be a detectable label or an immunotoxin.
  • Specific, non-limiting examples of toxins include, but are not limited to, abrin, ricin,
  • PE Pseudomonas exotoxin
  • DT diphtheria toxin
  • botulinum toxin or modified toxins thereof, or other toxic agents that directly or indirectly inhibit cell growth or kill cells.
  • PE and DT are highly toxic compounds that typically bring about death through liver toxicity.
  • PE and DT can be modified into a form for use as an immunotoxin by removing the native targeting component of the toxin (such as the domain la of PE and the B chain of DT) and replacing it with a different targeting moiety, such as an antibody.
  • a “chimeric molecule” is a targeting moiety, such as a ligand or an antibody, conjugated (coupled) to an effector molecule.
  • conjugated or “linked” refers to making two polypeptides into one contiguous polypeptide molecule.
  • an antibody is joined to an effector molecule.
  • an antibody joined to an effector molecule is further joined to a lipid or other molecule to a protein or peptide to increase its half-life in the body.
  • the linkage can be either by chemical or recombinant means.
  • the linkage is chemical, wherein a reaction between the antibody moiety and the effector molecule has produced a covalent bond formed between the two molecules to form one molecule.
  • a peptide linker short peptide sequence
  • chimeric molecules because immunoconjugates were originally prepared from two molecules with separate functionalities, such as an antibody and an effector molecule, they are also sometimes referred to as “chimeric molecules.”
  • Immunoliposome A liposome with antibodies or antibody fragments conjugated to its surface. Immunoliposomes can carry cytotoxic agents or other drugs to antibody -targeted cells, such as tumor cells.
  • Interstrand crosslinking agent A type of cytotoxic drug capable of binding covalently between two strands of DNA, thereby preventing DNA replication and/or transcription.
  • Isolated An "isolated" biological component, such as a nucleic acid, protein (including antibodies) or organelle, has been substantially separated or purified away from other biological components in the environment (such as a cell) in which the component naturally occurs, i.e. , other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles.
  • Nucleic acids and proteins that have been “isolated” include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids.
  • Label A detectable compound or composition that is conjugated directly or indirectly to another molecule, such as an antibody or a protein, to facilitate detection of that molecule.
  • labels include fluorescent tags, enzymatic linkages, and radioactive isotopes.
  • a "labeled antibody” refers to incorporation of another molecule in the antibody.
  • the label is a detectable marker, such as the
  • labels for polypeptides include, but are not limited to, the following: radioisotopes or radionucleotides (such as 35 S, n C, 13 N, 15 0, 18 F, 19 F, 99m Tc, m I, 3 H, 14 C, 15 N, 90 Y, 99 Tc, m In and 125 I), fluorescent labels (such as fluorescein isothiocyanate (FITC), rhodamine, lanthanide phosphors), enzymatic labels (such as horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), chemiluminescent markers, biotinyl groups, predetermined polypeptide epitopes recognized by a secondary reporter (such as a leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags), or magnetic agents, such as gadolinium chelates.
  • labels are attached by spacer arms of various lengths
  • Linker In some cases, a linker is a peptide within an antibody binding fragment (such as an Fv fragment) which serves to indirectly bond the variable heavy chain to the variable light chain. "Linker” can also refer to a peptide serving to link a targeting moiety, such as an antibody, to an effector molecule, such as a cytotoxin or a detectable label.
  • conjugating refers to making two polypeptides into one contiguous polypeptide molecule, or to covalently attaching a radionuclide or other molecule to a polypeptide, such as an scFv.
  • the terms include reference to joining a ligand, such as an antibody moiety, to an effector molecule.
  • the linkage can be either by chemical or recombinant means.
  • “Chemical means” refers to a reaction between the antibody moiety and the effector molecule such that there is a covalent bond formed between the two molecules to form one molecule.
  • Lymphoma A group of blood cell tumors that develop from lymphocytes. The two main categories of lymphoma are Hodgkin's lymphoma and non-Hodgkin's lymphoma.
  • Neoplasia malignancy, cancer or tumor: A neoplasm is an abnormal growth of tissue or cells that results from excessive cell division. Neoplastic growth can produce a tumor. The amount of a tumor in an individual is the "tumor burden" which can be measured as the number, volume, or weight of the tumor. A tumor that does not metastasize is referred to as “benign.” A tumor that invades the surrounding tissue and/or can metastasize is referred to as "malignant.”
  • a first nucleic acid sequence is operably linked with a second nucleic acid sequence when the first nucleic acid sequence is placed in a functional relationship with the second nucleic acid sequence.
  • a promoter such as the CMV promoter
  • operably linked DNA sequences are contiguous and, where necessary to join two protein-coding regions, in the same reading frame.
  • Pharmaceutical agent A chemical compound or composition capable of inducing a desired therapeutic or prophylactic effect when properly administered to a subject or a cell.
  • parenteral formulations usually comprise injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.
  • physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like
  • solid compositions such as powder, pill, tablet, or capsule forms
  • conventional non-toxic solid carriers can include, for example, pharmaceutical grades of mannitol, lactose, starch, or magnesium stearate.
  • compositions to be administered can contain minor amounts of non-toxic auxiliary substances, such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • non-toxic auxiliary substances such as wetting or emulsifying agents, preservatives, and pH buffering agents and the like, for example sodium acetate or sorbitan monolaurate.
  • Preventing a disease refers to inhibiting the full development of a disease.
  • Treating refers to a therapeutic intervention that ameliorates a sign or symptom of a disease or pathological condition after it has begun to develop, such as a reduction in tumor burden or a decrease in the number of size of metastases.
  • Treating refers to the reduction in the number or severity of signs or symptoms of a disease, such as cancer.
  • a purified peptide preparation is one in which the peptide or protein is more enriched than the peptide or protein is in its natural environment within a cell.
  • a preparation is purified such that the protein or peptide represents at least 50% of the total peptide or protein content of the preparation.
  • Substantial purification denotes purification from other proteins or cellular components.
  • a substantially purified protein is at least 60%, 70%, 80%, 90%, 95% or 98% pure.
  • a substantially purified protein is 90% free of other proteins or cellular components.
  • PDB Pyrrolobenzodiazepine
  • PBDs include naturally produced and isolated PBDs, chemically synthesized naturally occurring PBDs, and chemically synthesized non-naturally occurring PBDs. PBDs also include monomeric, dimeric and hybrid PBDs (for a review see Gerratana, Med Res Rev 32(2):254-293, 2012).
  • a recombinant nucleic acid or protein is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or by the artificial manipulation of isolated segments of nucleic acids, for example, by genetic engineering techniques.
  • Sample A biological specimen containing genomic DNA, RNA (including mRNA), protein, or combinations thereof, obtained from a subject. Examples include, but are not limited to, peripheral blood, tissue, cells, urine, saliva, tissue biopsy, fine needle aspirate, surgical specimen, and autopsy material. In one example, a sample includes a tumor biopsy.
  • Sequence identity The similarity between amino acid or nucleic acid sequences is expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity or homology); the higher the percentage, the more similar the two sequences are. Homologs or variants of a polypeptide or nucleic acid molecule will possess a relatively high degree of sequence identity when aligned using standard methods.
  • NCBI National Center for Biotechnology Information
  • blastp blastn
  • blastx blastx
  • tblastn tblastx
  • Homologs and variants of a VH of an antibody that specifically binds a CD33 polypeptide are typically characterized by possession of at least about 75%, for example at least about 80%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity counted over the full length alignment with the amino acid sequence of the antibody using the NCBI Blast 2.0, gapped blastp set to default parameters.
  • the Blast 2 sequences function is employed using the default BLOSUM62 matrix set to default parameters, (gap existence cost of 11, and a per residue gap cost of 1).
  • the alignment should be performed using the Blast 2 sequences function, employing the PAM30 matrix set to default parameters (open gap 9, extension gap 1 penalties). Proteins with even greater similarity to the reference sequences will show increasing percentage identities when assessed by this method, such as at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, or at least 99% sequence identity. When less than the entire sequence is being compared for sequence identity, homologs and variants will typically possess at least 80% sequence identity over short windows of 10-20 amino acids, and may possess sequence identities of at least 85% or at least 90% or 95% depending on their similarity to the reference sequence.
  • Small molecule A molecule, typically with a molecular weight less than about 1000
  • Daltons or in some embodiments, less than about 500 Daltons, wherein the molecule is capable of modulating, to some measurable extent, an activity of a target molecule.
  • Squamous cell carcinoma A type of cancer that begins in squamous cells, which are thin, flat cells that look like fish scales. Squamous cells are found in the tissue that forms the surface of the skin, the lining of the hollow organs of the body, and the passages of the respiratory and digestive tracts. SCC is also called epidermoid carcinoma.
  • Subject Living multi-cellular vertebrate organisms, a category that includes both human and veterinary subjects, including human and non-human mammals.
  • Synthetic Produced by artificial means in a laboratory, for example a synthetic nucleic acid or protein (for example, an antibody) can be chemically synthesized in a laboratory.
  • Therapeutically effective amount A quantity of a specific substance sufficient to achieve a desired effect in a subject being treated. For instance, this can be the amount necessary to inhibit or suppress growth of a tumor. In one embodiment, a therapeutically effective amount is the amount necessary to eliminate, reduce the size, or prevent metastasis of a tumor. When administered to a subject, a dosage will generally be used that will achieve target tissue concentrations (for example, in tumors) that has been shown to achieve a desired in vitro effect.
  • Toxin A molecule that is cytotoxic for a cell.
  • Toxins include abrin, ricin, Pseudomonas exotoxin (PE), diphtheria toxin (DT), botulinum toxin, saporin, restrictocin or gelonin, or modified toxins thereof.
  • PE and DT are highly toxic compounds that typically bring about death through liver toxicity.
  • PE and DT can be modified into a form for use as an immunotoxin by removing the native targeting component of the toxin (such as domain la of PE or the B chain of DT) and replacing it with a different targeting moiety, such as an antibody.
  • a nucleic acid molecule as introduced into a host cell, thereby producing a transformed host cell.
  • a vector may include nucleic acid sequences that permit it to replicate in a host cell, such as an origin of replication.
  • a vector may also include one or more selectable marker genes and other genetic elements known in the art.
  • ml 033-9 ml 033-10, ml 033-12, ml 033-15, ml 033-2 and ml033-4, bind to soluble recombinant CD33 and cell-surface CD33 with high affinity.
  • CDR1 residues 26-32
  • CDR2 residues 51-58
  • CDR3 residues 97-111 ml033-9 VL (SEQ ID NO: 3)
  • CDR1 residues 26-35
  • CDR2 residues 53-61
  • CDR3 residues 100-113 ml033-12 VL (SEQ ID NO: 11)
  • CDR1 residues 26-31
  • CDR2 residues 51-58
  • CDR3 residues 97-107 ml033-15 VL (SEQ ID NO: 15)
  • CDR1 residues 27-37
  • CDR2 residues 55-57
  • CDR3 residues 94-102 ml033-2 (SEQ ID NO: 17)
  • CDR1 residues 26-33
  • CDR2 residues 51-58
  • CDR3 residues 96-108 ml033-4 (SEQ ID NO: 19)
  • monoclonal antibodies and antigen-binding fragments that bind (such as specifically bind) CD33, such as cell-surface CD33 or soluble CD33.
  • the monoclonal antibody or antigen-binding fragment includes both a VH domain and a VL domain.
  • the monoclonal antibody is a VH single-domain monoclonal antibody.
  • the monoclonal antibody or antigen-binding fragment that binds CD33 includes at least one CDR sequence from antibody ml 033-9, ml033-10, ml 033-12, ml 033-15, ml 033-2 or ml 033-4.
  • the CDR sequences are determined using the IMGT, Kabat or Chothia numbering scheme.
  • the CD33-specific monoclonal antibody or antigen-binding fragment includes a VH domain and a VL domain
  • the VH domain of the antibody includes one, two or all three CDR sequences of SEQ ID NO: 2, SEQ ID NO: 6, SEQ ID NO: 10 or SEQ ID NO: 14, and/or the VL domain of the antibody includes one, two or all three CDR sequences of SEQ ID NO: 4, SEQ ID NO: 8, SEQ ID NO: 12 or SEQ ID NO: 16.
  • the CDR sequences of the antibody or antigen-binding fragment can be determined using any numbering scheme know to one of skill in the art, such as the IMGT, Kabat or Chothia numbering scheme.
  • the VH domain of the monoclonal antibody or antigen-binding fragment comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-32, 51-58 and 97-111 of SEQ ID NO: 2; and/or the VL domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 27-34, 55-57 and 94-102 of SEQ ID NO: 4.
  • the VH domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-35, 53-61 and 100-117 of SEQ ID NO: 6; and/or the VL domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-35, 51-53 and 90-100 of SEQ ID NO: 8.
  • the VH domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-35, 53-61 and 100-113 of SEQ ID NO: 10; and/or the VL domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-31, 49-51 and 88-98 of SEQ ID NO: 12.
  • the VH domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 26-31, 51-58 and 97-107 of SEQ ID NO: 14; and/or the VL domain comprises a CDRl, a CDR2 and a CDR3 respectively set forth as residues 27-37, 55-57 and 94-102 of SEQ ID NO: 16.
  • the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 2 and/or the amino acid sequence of the VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 4.
  • the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 6 and/or the amino acid sequence of the VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 8.
  • the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 10 and/or the amino acid sequence of the VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 12.
  • the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 14 and/or the amino acid sequence of the VL domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 16.
  • the sequence variation occurs only in the framework residues (not within the CDRs).
  • the amino acid sequence of the VH domain comprises SEQ ID NO: 2 and/or the amino acid sequence of the VL domain comprises SEQ ID NO: 4; the amino acid sequence of the VH domain comprises SEQ ID NO: 6 and/or the amino acid sequence of the VL domain comprises SEQ ID NO: 8; the amino acid sequence of the VH domain comprises SEQ ID NO: 10 and/or the amino acid sequence of the VL domain comprises SEQ ID NO: 12; or the amino acid sequence of the VH domain comprises SEQ ID NO: 14 and/or the amino acid sequence of the VL domain comprises SEQ ID NO: 16.
  • CD33-specific antigen-binding fragments that include both a VH domain and a VL domain can be, for example, an Fab fragment, an Fab' fragment, an F(ab)'2 fragment, a single chain variable fragment (scFv) or a disulfide stabilized variable fragment (dsFv).
  • the antigen-binding fragment is a scFv.
  • the antigen- binding fragment is a scFv.
  • CD33-specific monoclonal antibodies can be of any isotype, such as IgG, IgM, IgA, IgD or IgE.
  • the monoclonal antibody is an IgG.
  • the CD33-specific monoclonal antibody is a VH single-domain antibody that includes one, two or all three CDR sequences of SEQ ID NO: 18 or SEQ ID NO: 20.
  • the VH domain comprises residues 26-33, 51-58 and 96-108 of SEQ ID NO: 18, or residues 26-33, 51-58 and 97-102 of SEQ ID NO: 20.
  • the amino acid sequence of the VH domain is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 18 or SEQ ID NO: 20.
  • the sequence variation occurs only in the framework residues (not within the CDRs).
  • the amino acid sequence of the VH domain comprises or consists of the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 20.
  • the monoclonal antibody or antigen-binding fragment is a fully human antibody or antigen-binding fragment. In some embodiments, the monoclonal antibody or antigen-binding fragment is a chimeric or synthetic antibody or antigen-binding fragment.
  • immunoconjugates that include a monoclonal antibody or antigen-binding fragment disclosed herein and an effector molecule.
  • the effector molecule is a toxin, such as, but not limited to, Pseudomonas exotoxin or a variant thereof.
  • the effector molecule is a detectable label, such as, but not limited to, a fluorophore, an enzyme or a radioisotope.
  • Immunoconjugates are further described in section IV.
  • antibody-drug conjugates ADCs
  • the drug is a small molecule, for example an anti-microtubule agent, an antimitotic agent and/or a cytotoxic agent.
  • ADCs are further described in section V.
  • multi-specific antibodies that include a monoclonal antibody or antigen-binding fragment disclosed herein and at least one additional monoclonal antibody or antigen-binding fragment thereof.
  • the multi-specific antibody is a bispecific antibody. In other embodiments, the multi-specific antibody is a trispecific antibody. In some embodiments, the at least one additional monoclonal antibody or antigen binding fragment thereof specifically binds a component of the T cell receptor or a natural killer (NK) cell activating receptor.
  • NK natural killer
  • antibody -nanoparticle conjugates that include a nanoparticle conjugated to a monoclonal antibody or antigen-binding fragment disclosed herein.
  • the nanoparticle comprises a polymeric nanoparticle, nanosphere, nanocapsule, liposome, dendrimer, polymeric micelle, or niosome.
  • the nanoparticle includes a cytotoxic agent.
  • Antibody-nanoparticle conjugates are further described in section VII.
  • fusion proteins that include a monoclonal antibody or antigen- binding fragment disclosed herein and a heterologous protein or peptide.
  • the heterologous protein is an Fc protein.
  • the Fc protein is a mouse Fc or a human Fc protein.
  • the heterologous peptide is not endogenous to humans (for example, the heterologous peptide is a peptide neo-epitope).
  • the heterologous peptide is about 8 to about 20 amino acids in length. In particular examples, the heterologous peptide is about 14 amino acids in length.
  • compositions that include a pharmaceutically acceptable carrier and a monoclonal antibody or antigen-binding fragment, immunoconjugate, ADC, multi-specific antibody, antibody-nanoparticle conjugate, or fusion protein disclosed herein are further provided by the present disclosure.
  • nucleic acid molecules encoding a monoclonal antibody or antigen- binding fragment disclosed herein.
  • the nucleic acid molecule encodes a VH domain and is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ I DNO: 17 or SEQ ID NO: 19.
  • the nucleic acid molecule encoding the VH domain comprises or consists of SEQ ID NO: 1, SEQ ID NO: 5, SEQ ID NO: 9, SEQ ID NO: 13, SEQ I DNO: 17 or SEQ ID NO: 19.
  • the nucleic acid molecules encodes a VL domain and is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% identical to SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11 or SEQ ID NO: 15.
  • the nucleic acid molecule encoding the VL domain comprises or consists of SEQ ID NO: 3, SEQ ID NO: 7, SEQ ID NO: 11 or SEQ ID NO: 15.
  • the nucleic acid molecule comprises SEQ ID NO: 1 and SEQ ID NO: 3; SEQ ID NO: 5 and SEQ ID NO: 7; SEQ ID NO: 9 and SEQ ID NO: 11; or SEQ ID NO: 13 and SEQ ID NO: 15.
  • nucleic acid molecules encoding an immunoconjugate, multi- specific antibody, or fusion protein disclosed herein are provided.
  • the nucleic acid molecule is operably linked to a promoter.
  • the method includes administering to the subject a monoclonal antibody or antigen-binding fragment, immunoconjugate, ADC, multi-specific antibody, antibody- nanoparticle conjugate, fusion protein, or composition disclosed herein. Also provided is a method of inhibiting metastasis of a CD33-positive cancer in a subject. In some embodiments, the method includes administering to the subject a monoclonal antibody or antigen-binding fragment, immunoconjugate, ADC, multi-specific antibody, antibody-nanoparticle conjugate, fusion protein, or composition disclosed herein.
  • the CD33-positive cancer is acute myeloid leukemia (AML). In other examples, the CD33-positive cancer is a lymphoma or a squamous cell carcinoma.
  • the method includes contacting the sample with a CD33-specific monoclonal antibody or antigen-binding fragment disclosed herein; and detecting binding of the antibody to the sample.
  • the monoclonal antibody or antigen-binding fragment is directly labeled.
  • the method further includes contacting the monoclonal antibody or antigen-binding fragment with a second antibody, and detecting the binding of the second antibody to the monoclonal antibody or antigen-binding fragment.
  • the sample is obtained from a subject suspected of having a CD33-positive cancer.
  • the sample is a blood sample or a bone marrow biopsy.
  • the method includes contacting a sample from the subject with a CD33-specific monoclonal antibody antigen-binding fragment disclosed herein, and detecting binding of the antibody to the sample.
  • An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample identifies the subject as having a CD33-positive cancer.
  • the sample is a blood sample or a bone marrow biopsy.
  • the disclosed monoclonal antibodies can be conjugated to a therapeutic agent or effector molecule.
  • Immunoconjugates include, but are not limited to, molecules in which there is a covalent linkage of a therapeutic agent to an antibody.
  • a therapeutic agent is an agent with a particular biological activity directed against a particular target molecule or a cell bearing a target molecule.
  • therapeutic agents can include various drugs such as vinblastine, daunomycin and the like, cytotoxins such as native or modified
  • Pseudomonas exotoxin or diphtheria toxin encapsulating agents (such as liposomes) that contain pharmacological compositions, radioactive agents such as 125 1, 2 P, 14 C, 3 ⁇ 4 and 5 S and other labels, target moieties and ligands.
  • the choice of a particular therapeutic agent depends on the particular target molecule or cell, and the desired biological effect.
  • the therapeutic agent can be a cytotoxin that is used to bring about the death of a particular target cell (such as a tumor cell).
  • the therapeutic agent can be conjugated to a non-lethal pharmacological agent or a liposome containing a non-lethal pharmacological agent.
  • nucleic acids encoding antibodies and conjugates and fusion proteins thereof.
  • Effector molecules can be linked to an antibody of interest using any number of means known to those of skill in the art. Both covalent and noncovalent attachment means may be used.
  • the procedure for attaching an effector molecule to an antibody varies according to the chemical structure of the effector.
  • Polypeptides typically contain a variety of functional groups; such as carboxylic acid (COOH), free amine (-NH2) or sulfhydryl (-SH) groups, which are available for reaction with a suitable functional group on an antibody to result in the binding of the effector molecule.
  • the antibody is derivatized to expose or attach additional reactive functional groups.
  • the derivatization may involve attachment of any of a number of known linker molecules.
  • the linker can be any molecule used to join the antibody to the effector molecule.
  • the linker is capable of forming covalent bonds to both the antibody and to the effector molecule.
  • Suitable linkers are well known to those of skill in the art and include, but are not limited to, straight or branched-chain carbon linkers, heterocyclic carbon linkers, or peptide linkers.
  • the linkers may be joined to the constituent amino acids through their side groups (such as through a disulfide linkage to cysteine) or to the alpha carbon amino and carboxyl groups of the terminal amino acids.
  • immunoconjugates will comprise linkages that are cleavable in the vicinity of the target site. Cleavage of the linker to release the effector molecule from the antibody may be prompted by enzymatic activity or conditions to which the immunoconjugate is subjected either inside the target cell or in the vicinity of the target site.
  • the antibodies disclosed herein can be derivatized or linked to another molecule (such as another peptide or protein).
  • the antibodies or portion thereof is derivatized such that the binding to the target antigen is not affected adversely by the derivatization or labeling.
  • the antibody can be functionally linked (by chemical coupling, genetic fusion, noncovalent association or otherwise) to one or more other molecular entities, such as another antibody (for example, a bispecific antibody or a diabody), a detection agent, a pharmaceutical agent, and/or a protein or peptide that can mediate association of the antibody or antibody portion with another molecule (such as a streptavidin core region or a polyhistidine tag).
  • One type of derivatized antibody is produced by cross-linking two or more antibodies (of the same type or of different types, such as to create bispecific antibodies).
  • Suitable crosslinkers include those that are heterobifunctional, having two distinctly reactive groups separated by an appropriate spacer (such as m-maleimidobenzoyl-N-hydroxysuccinimide ester) or
  • the antibody can be conjugated with a detectable marker; for example, a detectable marker capable of detection by ELISA, spectrophotometry, flow cytometry, microscopy or diagnostic imaging techniques (such as computed tomography (CT), computed axial tomography
  • a detectable marker capable of detection by ELISA, spectrophotometry, flow cytometry, microscopy or diagnostic imaging techniques (such as computed tomography (CT), computed axial tomography
  • detectable markers include fluorophores, chemiluminescent agents, enzymatic linkages, radioactive isotopes and heavy metals or compounds (for example super paramagnetic iron oxide nanocrystals for detection by MRI).
  • useful detectable markers include fluorescent compounds, including fluorescein, fluorescein isothiocyanate, rhodamine, 5-dimethylamine-l-napthalenesulfonyl chloride, phycoerythrin, lanthanide phosphors and the like.
  • Bioluminescent markers are also of use, such as luciferase, green fluorescent protein (GFP) and yellow fluorescent protein (YFP).
  • An antibody or antigen binding fragment can also be conjugated with enzymes that are useful for detection, such as horseradish peroxidase, ⁇ - galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like.
  • enzymes that are useful for detection, such as horseradish peroxidase, ⁇ - galactosidase, luciferase, alkaline phosphatase, glucose oxidase and the like.
  • an antibody or antigen binding fragment may also be conjugated with biotin, and detected through indirect measurement of avidin or streptavidin binding. It should be noted that the avidin itself can be conjugated with an enzyme or a fluorescent label.
  • An antibody may be labeled with a magnetic agent, such as gadolinium.
  • Antibodies can also be labeled with lanthanides (such as europium and dysprosium), and manganese.
  • Paramagnetic particles such as superparamagnetic iron oxide are also of use as labels.
  • An antibody may also be labeled with a predetermined polypeptide epitopes recognized by a secondary reporter (such as leucine zipper pair sequences, binding sites for secondary antibodies, metal binding domains, epitope tags).
  • labels are attached by spacer arms of various lengths to reduce potential steric hindrance.
  • An antibody can also be labeled with a radiolabeled amino acid.
  • the radiolabel may be used for both diagnostic and therapeutic purposes.
  • the radiolabel may be used to detect expression of a target antigen by x-ray, emission spectra, or other diagnostic techniques.
  • Examples of labels for polypeptides include, but are not limited to, the following radioisotopes or radionucleotides: 3 ⁇ 4, 14 C, 15 N, 35 S, 90 Y, "Tc, m In, 125 1, 13 3 ⁇ 4.
  • An antibody can also be derivatized with a chemical group such as polyethylene glycol (PEG), a methyl or ethyl group, or a carbohydrate group. These groups may be useful to improve the biological characteristics of the antibody, such as to increase serum half-life or to increase tissue binding.
  • PEG polyethylene glycol
  • methyl or ethyl group a methyl or ethyl group
  • carbohydrate group a chemical group such as polyethylene glycol (PEG), a methyl or ethyl group, or a carbohydrate group.
  • Toxins can be employed with the monoclonal antibodies described herein to produce immunotoxins.
  • Exemplary toxins include ricin, abrin, diphtheria toxin and subunits thereof, as well as botulinum toxins A through F. These toxins are readily available from commercial sources (for example, Sigma Chemical Company, St. Louis, MO). Contemplated toxins also include variants of the toxins described herein (see, for example, see, U.S. Patent Nos. 5,079,163 and 4,689,401).
  • the toxin is Pseudomonas exotoxin (PE) (U.S. Patent No.
  • Pseudomonas exotoxin refers to a full-length native (naturally occurring) PE or a PE that has been modified. Such modifications can include, but are not limited to, elimination of domain la, various amino acid deletions in domains lb, II and III, single amino acid substitutions and the addition of one or more sequences at the carboxyl terminus (for example, see Siegall et al., J. Biol. Chem. 264: 14256-14261, 1989).
  • PE employed with the monoclonal antibodies described herein can include the native sequence, cytotoxic fragments of the native sequence, and conservatively modified variants of native PE and its cytotoxic fragments. Cytotoxic fragments of PE include those which are cytotoxic with or without subsequent proteolytic or other processing in the target cell. Cytotoxic fragments of PE include PE40, PE38, and PE35. For additional description of PE and variants thereof, see for example, U.S. Patent Nos. 4,892,827; 5,512,658; 5,602,095; 5,608,039;
  • PE-LR protease-resistant PE variants and PE variants with reduced immunogenicity
  • PE-LR protease-resistant PE variants and PE variants with reduced immunogenicity
  • PE-LR protease-resistant PE variants and PE variants with reduced immunogenicity
  • PE-LR protease-resistant PE variants and PE variants with reduced immunogenicity
  • PE-LR protease-resistant PE variants and PE variants with reduced immunogenicity
  • the PE is a variant that is resistant to lysosomal degradation, such as
  • PE-LR (Weldon et al, Blood 113(16):3792-3800, 2009; PCT Publication No. WO 2009/032954).
  • the PE is a variant designated PE-LR/6X (PCT Publication No. WO
  • the PE variant is PE with reducing immunogenicity.
  • the PE is a variant designated PE-LR/8M (PCT Publication No. WO
  • Modification of PE may occur in any previously described variant, including cytotoxic fragments of PE (for example, PE38, PE-LR and PE-LR/8M).
  • Modified PEs may include any substitution(s), such as for one or more amino acid residues within one or more T-cell epitopes and/or B cell epitopes of PE, or deletion of one or more T-cell and/or B-cell epitopes (see, for example, U.S. Patent Application Publication No. 2015/0099707).
  • Contemplated forms of PE also include deimmunized forms of PE, for example versions with domain II deleted (for example, PE24).
  • Deimmunized forms of PE are described in, for example, PCT Publication Nos. WO 2005/052006, WO 2007/016150, WO 2007/014743, WO 2007/031741, WO 2009/32954, WO 2011/32022, WO 2012/154530, and WO 2012/170617.
  • the antibodies described herein can also be used to target any number of different diagnostic or therapeutic compounds to cells expressing the tumor or viral antigen on their surface.
  • an antibody of the present disclosure can be attached directly or via a linker to a drug that is to be delivered directly to cells expressing cell-surface antigen. This can be done for therapeutic, diagnostic or research purposes.
  • Therapeutic agents include such compounds as nucleic acids, proteins, peptides, amino acids or derivatives, glycoproteins, radioisotopes, lipids, carbohydrates, or recombinant viruses.
  • Nucleic acid therapeutic and diagnostic moieties include antisense nucleic acids, derivatized oligonucleotides for covalent cross-linking with single or duplex DNA, and triplex forming oligonucleotides.
  • the molecule linked to an antibody can be an encapsulation system, such as a nanoparticle, liposome or micelle that contains a therapeutic composition such as a drug, a nucleic acid (for example, an antisense nucleic acid), or another therapeutic moiety that is preferably shielded from direct exposure to the circulatory system.
  • a therapeutic composition such as a drug, a nucleic acid (for example, an antisense nucleic acid), or another therapeutic moiety that is preferably shielded from direct exposure to the circulatory system.
  • Means of preparing liposomes attached to antibodies are well known to those of skill in the art (see, for example, U.S. Patent No. 4,957,735; Connor e/ 1 al , Pharm. Ther. 28:341-365, 1985).
  • Antibodies described herein can also be covalently or non-covalently linked to a detectable label.
  • Detectable labels suitable for such use include any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means.
  • Useful labels include magnetic beads, fluorescent dyes (for example, fluorescein isothiocyanate, Texas red, rhodamine, green fluorescent protein, and the like), radiolabels (for example, 3 ⁇ 4, 125 1, 5 S, 14 C, or 2 P), enzymes (such as horseradish peroxidase, alkaline phosphatase and others commonly used in an ELISA), and colorimetric labels such as colloidal gold or colored glass or plastic (such as polystyrene, polypropylene, latex, and the like) beads.
  • fluorescent dyes for example, fluorescein isothiocyanate, Texas red, rhodamine, green fluorescent protein, and the like
  • radiolabels for example, 3 ⁇ 4, 125 1,
  • radiolabels may be detected using photographic film or scintillation counters
  • fluorescent markers may be detected using a photodetector to detect emitted illumination.
  • Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label.
  • ADCs Antibody-Drug Conjugates
  • ADCs are compounds comprised of a tumor antigen-specific antibody (or antigen-binding fragment thereof) and a drug, typically a cytotoxic agent, such as an anti-microtubule agent or cross-linking agent. Because ADCs are capable of specifically targeting cancer cells, the drug can be much more potent than agents used for standard chemotherapy.
  • cytotoxic drugs currently used with ADCs have an IC50 that is 100- to 1000-fold more potent than conventional chemotherapeutic agents.
  • Common cytotoxic drugs include anti-microtubule agents, such as maytansinoids and auristatins (such as auristatin E and auristatin F).
  • cytotoxins for use with ADCs include pyrrolobenzodiazepines (PDBs), which covalently bind the minor groove of DNA to form interstrand crosslinks.
  • PDBs pyrrolobenzodiazepines
  • ADCs comprise a 1:2 to 1:4 ratio of antibody to drug (Bander, Clinical Advances in Hematology & Oncology 10(8; suppl 10):3-7, 2012).
  • the antibody and drug can be linked by a cleavable or non-cleavable linker.
  • a linker that is stable in the circulation to prevent systemic release of the cytotoxic drug that could result in significant off-target toxicity.
  • Non-cleavable linkers prevent release of the cytotoxic agent before the ADC is internalized by the target cell. Once in the lysosome, digestion of the antibody by lysosomal proteases results in the release of the cytotoxic agent (Bander, Clinical Advances in Hematology & Oncology 10(8; suppl 10):3-7, 2012).
  • Monoclonal antibodies have one conserved N-linked oligosaccharide chain at the Asn297 residue in the CH2 domain of each heavy chain (Qasba et al. , Biotechnol Prog 24:520-526, 2008).
  • Y289L-Gal-Tl a mutant pi,4-galactosyltransferase enzyme
  • 2-keto-galactose is transferred to free GlcNAc residues on the antibody heavy chain to provide a chemical handle for conjugation.
  • the oligosaccharide chain attached to monoclonal antibodies can be classified into three groups based on the terminal galactose residues - fully galactosylated (two galactose residues; IgG-G2), one galactose residue (IgG-Gl) or completely degalactosylated (IgG-GO).
  • Treatment of a monoclonal antibody with pi,4-galactosidase converts the antibody to the IgG-GO glycoform.
  • the mutant pi,4-galactosyltransferase enzyme is capable of transferring 2-keto- galactose or 2-azido-galactose from their respective UDP derivatives to the GlcNAc residues on the IgG-Gl and IgG-GO glycoforms.
  • the chemical handle on the transferred sugar enables conjugation of a variety of molecules to the monoclonal antibody via the glycan residues (Qasba et al., Biotechnol Prog 24:520-526, 2008).
  • ADCs that include a drug (such as a cytotoxic agent) conjugated to a monoclonal antibody that binds (such as specifically binds) CD33.
  • the drug is a small molecule.
  • the drug is a cross-linking agent, an anti- microtubule agent and/or anti-mitotic agent, or any cytotoxic agent suitable for mediating killing of tumor cells.
  • cytotoxic agents include, but are not limited to, a PDB, an auristatin, a maytansinoid, dolastatin, calicheamicin, nemorubicin and its derivatives, PNU-159682, anthracycline, vinca alkaloid, taxane, trichothecene, CC1065, camptothecin, elinafide, a combretastain, a dolastatin, a duocarmycin, an enediyne, a geldanamycin, an indolino- benzodiazepine dimer, a puromycin, a tubulysin, a hemiasterlin, a spliceostatin, or a pladienolide, as well as stereoisomers, isosteres, analogs, and derivatives thereof that have cytotoxic activity.
  • PDB auristatin
  • a maytansinoid dolastatin
  • the ADC comprises a pyrrolobenzodiazepine (PBD).
  • PBD pyrrolobenzodiazepine
  • the natural product anthramycin (a PBD) was first reported in 1965 (Leimgruber et al, J Am Chem Soc, 87:5793-5795, 1965; Leimgruber et al. , J Am Chem Soc, 87:5791-5793, 1965). Since then, a number of PBDs, both naturally-occurring and synthetic analogues, have been reported
  • PDB dimers recognize and bind to specific DNA sequences, and have been shown to be useful as cytotoxic agents.
  • PBD dimers have been conjugated to antibodies and the resulting ADC shown to have anti-cancer properties (see, for example, US 2010/0203007).
  • Exemplary linkage sites on the PBD dimer include the five-membered pyrrolo ring, the tether between the PBD units, and the N10-C11 imine group (see WO 2009/016516; US 2009/304710; US 2010/047257; US
  • the ADC comprises an antibody conjugated to one or more maytansinoid molecules.
  • Maytansinoids are derivatives of maytansine, and are mitotic inhibitors which act by inhibiting tubulin polymerization. Maytansine was first isolated from the east African shrub Maytenus serrata (U.S. Patent No. 3,896,111). Subsequently, it was discovered that certain microbes also produce maytansinoids, such as maytansinol and C-3 maytansinol esters (U.S. Patent No. 4,151,042). Synthetic maytansinoids are disclosed, for example, in U.S. Patent Nos. 4,137,230; 4,248,870; 4,256,746; 4,260,608; 4,265,814; 4,294,757; 4,307,016;
  • the ADC includes an antibody conjugated to a dolastatin or auristatin, or an analog or derivative thereof (see U.S. Patent Nos. 5,635,483; 5,780,588;
  • Auristatins are derivatives of the marine mollusk compound dolastatin- 10. Dolastatins and auristatins have been shown to interfere with microtubule dynamics, GTP hydrolysis, and nuclear and cellular division (Woyke et al. , Antimicrob Agents and Chemother 45(12):3580-3584, 2001) and have anticancer (U.S. Patent No. 5,663,149) and antifungal activity (Pettit et al, Antimicrob Agents Chemother 42:2961-2965, 1998).
  • Exemplary dolastatins and auristatins include, but are not limited to, dolastatin 10, auristatin E, auristatin F, auristatin EB (AEB), auristatin EFP (AEFP), MMAD (Monomethyl Auristatin D or monomethyl dolastatin 10), MMAF (Monomethyl Auristatin F or N-methylvaline-valine-dolaisoleuine- dolaproine-phenylalanine), MMAE (Monomethyl Auristatin E or N-methylvaline-valine- dolaisoleuine-dolaproine-norephedrine), 5-benzoylvaleric acid-AE ester (AEVB), and other auristatins (see, for example, U.S. Publication No. 2013/0129753).
  • the ADC comprises an antibody conjugated to one or more calicheamicin molecules.
  • the calicheamicin family of antibiotics, and analogues thereof, are capable of producing double-stranded DNA breaks at sub-picomolar concentrations (Hinman et al. , Cancer Res 53:3336-3342, 1993; Lode et al , Cancer Res 58:2925-2928, 1998).
  • Exemplary methods for preparing ADCs with a calicheamicin drug moiety are described in U.S. Patent Nos. 5,712,374; 5,714,586; 5,739,116; and 5,767,285.
  • the ADC comprises an anthracycline.
  • Anthracyclines are antibiotic compounds that exhibit cytotoxic activity. It is believed that anthracyclines can operate to kill cells by a number of different mechanisms, including intercalation of the drug molecules into the DNA of the cell thereby inhibiting DNA-dependent nucleic acid synthesis; inducing production of free radicals which then react with cellular macromolecules to cause damage to the cells; and/or interactions of the drug molecules with the cell membrane.
  • Non- limiting exemplary anthracyclines include doxorubicin, epirubicin, idarubicin, daunomycin, daunorubicin, doxorubicin, epirubicin, nemorubicin, valrubicin and mitoxantrone, and derivatives thereof.
  • PNU-159682 is a potent metabolite (or derivative) of nemorubicin (Quintieri et al , Clin Cancer Res 11(4): 1608-1617, 2005).
  • Nemorubicin is a semisynthetic analog of doxorubicin with a 2-methoxymorpholino group on the glycoside amino of doxorubicin (Grandi et al , Cancer Treat Rev 17: 133, 1990; Ripamonti et al, Br J Cancer 65:703-707, 1992).
  • the ADC can further include a linker.
  • the linker is a bifunctional or multifunctional moiety that can be used to link one or more drug moieties to an antibody to form an ADC.
  • ADCs are prepared using a linker having reactive functionalities for covalently attaching to the drug and to the antibody. For example, a cysteine thiol of an antibody can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.
  • a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond.
  • exemplary linkers with such reactive functionalities include maleimide, haloacetamides, a-haloacetyl, activated esters such as succinimide esters, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates.
  • a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody.
  • electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups.
  • a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit.
  • Non-limiting examples include hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate and arylhydrazide.
  • the linker is a cleavable linker, which facilitates release of the drug.
  • cleavable linkers include acid-labile linkers (for example, comprising hydrazone), protease-sensitive linkers (for example, peptidase-sensitive), photolabile linkers, and disulfide- containing linkers (Chari et al, Cancer Res 52: 127-131, 1992; U.S. Patent No. 5,208,020).
  • the ADCs disclosed herein can be used for the treatment of a CD33-positive cancer alone or in combination with another therapeutic agent and/or in combination with any standard therapy for the treatment of cancer (such as surgical resection of the tumor, chemotherapy or radiation therapy).
  • Multi-specific antibodies are recombinant proteins comprised of antigen-binding fragments of two or more different monoclonal antibodies.
  • bispecific antibodies are comprised of antigen-binding fragments of two different monoclonal antibodies.
  • bispecific antibodies bind two different antigens and trispecific antibodies bind three different antigens.
  • Multi-specific antibodies can be used for cancer immunotherapy by simultaneously targeting, for example, both CTLs (such as a CTL receptor component such as CD3) or effector natural killer (NK) cells, and at least one tumor antigen.
  • CTLs such as a CTL receptor component such as CD3
  • NK effector natural killer
  • CD33-specific monoclonal antibodies disclosed herein can be used to generate multi-specific (such as bispecific or trispecific) antibodies that target both CD33 and CTLs, or target both CD33 and NK cells, thereby providing a means to treat CD33-expressing cancers.
  • Bi-specific T-cell engagers are a type of bispecific monoclonal antibody that are fusions of a first single-chain variable fragment (scFv) that targets a tumor antigen and a second scFv that binds T cells, such as bind CD3 on T cells.
  • scFv single-chain variable fragment
  • a second scFv that binds T cells, such as bind CD3 on T cells.
  • one of the binding moieties of the BiTE (such as one of the scFv molecules) is specific for CD33.
  • Bi-specific killer cell engagers are a type of bispecific monoclonal antibody that are fusions of a first scFv that targets a tumor antigen and a second scFv that binds a NK cell activating receptor, such as CD16.
  • a NK cell activating receptor such as CD16.
  • multi-specific, such as trispecific or bispecific, monoclonal antibodies comprising a CD33-specific monoclonal antibody.
  • the multi-specific monoclonal antibody further comprises a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds a component of the T cell receptor, such as CD3.
  • the multi-specific monoclonal antibody further comprises a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds a NK cell activating receptor, such as CD 16, Ly49, or CD94.
  • a monoclonal antibody, or antigen-binding fragment thereof that specifically binds a NK cell activating receptor, such as CD 16, Ly49, or CD94.
  • isolated nucleic acid molecules and vectors encoding the multi-specific antibodies, and host cells comprising the nucleic acid molecules or vectors.
  • Multi-specific antibodies comprising a CD33-specific antibody can be used for the treatment of cancers that express CD33.
  • methods of treating a subject with cancer by selecting a subject with a cancer that expresses CD33, and administering to the subject a therapeutically effective amount of the CD33-targeting multi-specific antibody.
  • the monoclonal antibodies disclosed herein can be conjugated to a variety of different types of nanoparticles to deliver cytotoxic agents or other anti-cancer agents directly to tumor cells via binding of the antibody to a tumor specific antigen (e.g. CD33) expressed on the surface of tumor cells.
  • a tumor specific antigen e.g. CD33
  • the use of nanoparticles reduces off-target side effects and can also improve drug bioavailability and reduce the dose of a drug required to achieve a therapeutic effect.
  • Nanoparticle formulations can be tailored to suit the drug that is to be carried or encapsulated within the nanoparticle.
  • hydrophobic molecules can be incorporated inside the core of a nanoparticle
  • hydrophilic drugs can be carried within an aqueous core protected by a polymeric or lipid shell.
  • nanoparticles include, but at not limited to, nanospheres, nanocapsules, liposomes, dendrimers, polymeric micelles, niosomes, and polymeric
  • Liposomes are currently one of the most common types of nanoparticles used for drug delivery.
  • An antibody conjugated to a liposome is often referred to as an "immunoliposome.”
  • the liposomal component of an immunoliposome is typically a lipid vesicle of one or more concentric phospholipid bilayers.
  • the phospholipids are composed of a hydrophilic head group and two hydrophobic chains to enable encapsulation of both hydrophobic and hydrophilic drugs.
  • Conventional liposomes are rapidly removed from the circulation via macrophages of the reticuloendothelial system (RES). To generate long-circulating liposomes, the composition, size and charge of the liposome can be modulated.
  • RES reticuloendothelial system
  • the surface of the liposome may also be modified, such as with a glycolipid or sialic acid.
  • a glycolipid or sialic acid for example, the inclusion of polyethylene glycol (PEG) significantly increases circulation half-life.
  • PEG polyethylene glycol
  • Niosomes are non-ionic surfactant-based vesicles having a structure similar to liposomes.
  • the membranes of niosomes are composed only of nonionic surfactants, such as polyglyceryl- alkyl ethers or N-palmitoylglucosamine.
  • Niosomes range from small, unilamellar to large, multilamellar particles. These nanoparticles are monodisperse, water-soluble, chemically stable, have low toxicity, are biodegradable and non-immunogenic, and increase bioavailability of encapsulated drugs .
  • Dendrimers include a range of branched polymer complexes. These nanoparticles are water-soluble, biocompatible and are sufficiently non-immunogenic for human use. Generally, dendrimers consist of an initiator core, surrounded by a layer of a selected polymer that is grafted to the core, forming a branched macromolecular complex. Dendrimers are typically produced using polymers such as poly (ami doamine) or poly (L-ly sine). Dendrimers have been used for a variety of therapeutic and diagnostic applications, including for the delivery of DNA, RNA, bioimaging contrast agents and chemotherapeutic agents.
  • Polymeric micelles are composed of aggregates of amphiphilic co-polymers (consisting of both hydrophilic and hydrophobic monomer units) assembled into hydrophobic cores, surrounded by a corona of hydrophilic polymeric chains exposed to the aqueous environment.
  • the polymers used to prepare polymeric micelles are heterobifunctional copolymers composed of a hydrophilic block of PEG, poly (vinyl pyrrolidone) and hydrophobic poly(L- lactide) or poly(L-lysine) that forms the particle core.
  • Polymeric micelles can be used to carry drugs that have poor solubility. These nanoparticles have been used to encapsulate a number of anti-cancer drugs, including doxorubicin and camptothecin. Cationic micelles have also been developed to carry DNA or RNA molecules.
  • Nanospheres consist of a solid matrix of polymer, while nanocapsules contain an aqueous core.
  • the formulation selected typically depends on the solubility of the therapeutic agent to be carried/encapsulated; poorly water-soluble drugs are more readily encapsulated within a nanospheres, while water-soluble and labile drugs, such as DNA and proteins, are more readily encapsulated within nanocapsules.
  • the polymers used to produce these nanoparticles include, for example, poly(acrylamide), poly(ester), poly(alkylcyanoacrylates), poly(lactic acid) (PLA), poly(gly colic acids) (PGA), and poly(D,L-lactic-co-gly colic acid) (PLGA).
  • Antibodies can be conjugated to a suitable nanoparticle according to standard methods known in the art.
  • conjugation can be either covalent or non-covalent.
  • the nanoparticle is a liposome
  • the antibody is attached to a sterically stabilized, long circulation liposome via a PEG chain.
  • Coupling of antibodies or antibody fragments to a liposome can also involve thioester bonds, for example by reaction of thiols and maleimide groups.
  • Cross-linking agents can be used to create sulfhydryl groups for attachment of antibodies to nanoparticles (Paszko and Senge, Curr Med Chem 19(31)5239-5277, 2012).
  • compositions include one or more of the disclosed monoclonal antibodies that bind (for example specifically bind) CD33 in a carrier.
  • Compositions comprising ADCs, multi-specific (such as bispecific or trispecific) antibodies, antibody -nanoparticle conjugates, immunoliposomes and immunoconjugates are also provided.
  • the compositions can be prepared in unit dosage forms for administration to a subject. The amount and timing of administration are at the discretion of the treating clinician to achieve the desired outcome.
  • the antibody, ADC, multi-specific antibody, antibody-nanoparticle conjugate, immunoliposome or immunoconjugate can be formulated for systemic or local administration. In one example, the antibody is formulated for parenteral administration, such as intravenous administration.
  • compositions for administration can include a solution of the antibody, ADC, multi- specific (such as bispecific or trispecific) antibody, antibody-nanoparticle conjugate, immunoliposome or immunoconjugate in a pharmaceutically acceptable carrier, such as an aqueous carrier.
  • a pharmaceutically acceptable carrier such as an aqueous carrier.
  • a variety of aqueous carriers can be used, for example, buffered saline and the like. These solutions are sterile and generally free of undesirable matter.
  • These compositions may be sterilized by conventional, well known sterilization techniques.
  • the compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate
  • physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like.
  • concentration of antibody in these formulations can vary widely, and will be selected primarily based on fluid volumes, viscosities, body weight and the like in accordance with the particular mode of administration selected and the subject's needs.
  • a typical pharmaceutical composition for intravenous administration includes about 0.1 to 10 mg of antibody (or ADC, multi-specific antibody, antibody-nanoparticle conjugate, or immunoconjugate) per subject per day. Dosages from 0.1 up to about 100 mg per subject per day may be used, particularly if the agent is administered to a secluded site and not into the circulatory or lymph system, such as into a body cavity or into a lumen of an organ. Actual methods for preparing administrable compositions will be known or apparent to those skilled in the art and are described in more detail in such publications as Remington 's Pharmaceutical Science, 19th ed. , Mack Publishing Company, Easton, PA (1995).
  • Antibodies may be provided in lyophilized form and rehydrated with sterile water before administration, although they are also provided in sterile solutions of known concentration. The antibody solution is then added to an infusion bag containing 0.9% sodium chloride, USP, and in some cases administered at a dosage of from 0.5 to 15 mg/kg of body weight.
  • an infusion bag containing 0.9% sodium chloride, USP, and in some cases administered at a dosage of from 0.5 to 15 mg/kg of body weight.
  • Antibodies, ADCs, multi-specific (such as bispecific or trispecific) antibodies, antibody- nanoparticle conjugates, immunoliposomes or immunoconjugates can be administered by slow infusion, rather than in an intravenous push or bolus.
  • a higher loading dose is administered, with subsequent, maintenance doses being administered at a lower level.
  • an initial loading dose of 4 mg/kg may be infused over a period of some 90 minutes, followed by weekly maintenance doses for 4-8 weeks of 2 mg/kg infused over a 30 minute period if the previous dose was well tolerated.
  • Controlled release parenteral formulations can be made as implants, oily injections, or as particulate systems.
  • protein delivery systems see, Banga, A.J.,
  • Particulate systems include, for example, microspheres, microparticles, microcapsules, nanocapsules, nanospheres, and nanoparticles.
  • Microcapsules contain the therapeutic protein, such as a cytotoxin or a drug, as a central core. In microspheres the therapeutic is dispersed throughout the particle.
  • Particles, microspheres, and microcapsules smaller than about 1 ⁇ are generally referred to as nanoparticles, nanospheres, and nanocapsules, respectively.
  • Capillaries have a diameter of approximately 5 ⁇ so that only nanoparticles are administered intravenously.
  • Microparticles are typically around 100 ⁇ in diameter and are administered subcutaneously or intramuscularly. See, for example, Kreuter, J., Colloidal Drug Delivery Systems , J. Kreuter, ed., Marcel Dekker, Inc., New York, NY, pp. 219- 342 (1994); and Tice & Tabibi, Treatise on Controlled Drug Delivery, A. Kydonieus, ed.,
  • Polymers can be used for ion-controlled release of the antibody-based compositions disclosed herein.
  • Various degradable and nondegradable polymeric matrices for use in controlled drug delivery are known in the art (Langer, Accounts Chem. Res. 26:537-542, 1993).
  • the block copolymer, polaxamer 407 exists as a viscous yet mobile liquid at low temperatures but forms a semisolid gel at body temperature. It has been shown to be an effective vehicle for formulation and sustained delivery of recombinant interleukin-2 and urease (Johnston et al, Pharm. Res. 9:425-434, 1992; and Pec et al, J. Parent. Sci. Tech. 44(2):58-65, 1990).
  • hydroxyapatite has been used as a microcarrier for controlled release of proteins (Ijntema et al. , Int. J. Pharm. 112:215-224, 1994).
  • liposomes are used for controlled release as well as drug targeting of the lipid-capsulated drug (Betageri et al, Liposome Drug Delivery Systems, Technomic Publishing Co., Inc., Lancaster, PA (1993)).
  • Numerous additional systems for controlled delivery of therapeutic proteins are known (see U.S. Patent Nos. 5,055,303; 5,188,837; 4,235,871 ; 4,501,728; 4,837,028; 4,957,735; 5,019,369; 5,055,303;
  • the antibodies, compositions, ADCs, multi-specific (such as bispecific or trispecific) antibodies, antibody-nanoparticle conjugates, immunoliposomes and immunoconjugates disclosed herein can be administered to slow or inhibit the progression of a CD33-positive cancer, or inhibit the metastasis of a CD33-positive cancer.
  • a CD33-positive cancer or inhibit the metastasis of a CD33-positive cancer.
  • a composition is administered to a subject in an amount sufficient to inhibit growth, replication or metastasis of cancer cells, or to inhibit a sign or a symptom of the cancer.
  • Suitable subjects may include those diagnosed with a cancer that expresses CD33, such as AML, a lymphoma or a squamous cell carcinoma.
  • a method of treating a CD33-positive cancer in a subject by administering to the subject a therapeutically effective amount of a CD33-specific antibody, immunoconjugate, ADC, multi-specific (such as bispecific or trispecific) antibody, antibody- nanoparticle conjugate, immunoliposome or composition disclosed herein.
  • a method of inhibiting metastasis of a CD33-positive cancer in a subject by administering to the subject a therapeutically effective amount of a CD33-specific antibody, immunoconjugate, ADC, multi-specific (such as bispecific or trispecific) antibody, antibody-nanoparticle conjugate, immunoliposome or composition disclosed herein.
  • the CD33-positive cancer is AML.
  • the CD33-positive cancer is a lymphoma or a squamous cell carcinoma.
  • a therapeutically effective amount of a CD33-specific monoclonal antibody, ADC, multi- specific (such as bispecific or trispecific) antibody, immunoconjugate, immunoliposome or composition disclosed herein will depend upon the severity of the disease, the type of disease, and the general state of the patient's health.
  • a therapeutically effective amount of the antibody - based composition is that which provides either subjective relief of a symptom(s) or an objectively identifiable improvement as noted by the clinician or other qualified observer.
  • CD33-specific antibodies, ADCs, immunoconjugates, multi- specific (such as bispecific or trispecific) antibodies, antibody -nanoparticle conjugates, immunoliposomes and compositions disclosed herein can also be accompanied by administration of other anti-cancer agents or therapeutic treatments (such as surgical resection of a tumor). Any suitable anti-cancer agent can be administered in combination with the antibodies, compositions and immunoconjugates disclosed herein.
  • anti-cancer agents include, but are not limited to, chemotherapeutic agents, such as, for example, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti-survival agents, biological response modifiers, anti-hormones (e.g. anti-androgens) and anti-angiogenesis agents.
  • chemotherapeutic agents such as, for example, mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, anti-survival agents, biological response modifiers, anti-hormones (e.g. anti-androgens) and anti-angiogenesis agents.
  • Other anti-cancer treatments include radiation therapy and other antibodies that specifically target cancer cells.
  • alkylating agents include nitrogen mustards (such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard or chlorambucil), alkyl sulfonates (such as busulfan), nitrosoureas (such as carmustine, lomustine, semustine, streptozocin, or dacarbazine).
  • nitrogen mustards such as mechlorethamine, cyclophosphamide, melphalan, uracil mustard or chlorambucil
  • alkyl sulfonates such as busulfan
  • nitrosoureas such as carmustine, lomustine, semustine, streptozocin, or dacarbazine.
  • Non-limiting examples of antimetabolites include folic acid analogs (such as
  • methotrexate methotrexate
  • pyrimidine analogs such as 5-FU or cytarabine
  • purine analogs such as mercaptopurine or thioguanine.
  • Non-limiting examples of natural products include vinca alkaloids (such as vinblastine, vincristine, or vindesine), epipodophyllotoxins (such as etoposide or teniposide), antibiotics (such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitomycin C), and enzymes (such as L-asparaginase).
  • vinca alkaloids such as vinblastine, vincristine, or vindesine
  • epipodophyllotoxins such as etoposide or teniposide
  • antibiotics such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin, or mitomycin C
  • enzymes such as L-asparaginase
  • miscellaneous agents include platinum coordination complexes
  • cis-diamine-dichloroplatinum II also known as cisplatin
  • substituted ureas such as hydroxyurea
  • methyl hydrazine derivatives such as procarbazine
  • adrenocrotical suppressants such as mitotane and aminoglutethimide
  • hormones and antagonists include adrenocorticosteroids (such as prednisone), progestins (such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and magestrol acetate), estrogens (such as diethylstilbestrol and ethinyl estradiol), antiestrogens
  • adrenocorticosteroids such as prednisone
  • progestins such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and magestrol acetate
  • estrogens such as diethylstilbestrol and ethinyl estradiol
  • antiestrogens such as diethylstilbestrol and ethinyl estradiol
  • tamoxifen such as tamoxifen
  • androgens such as testerone proprionate and fluoxymesterone
  • chemotherapy drugs examples include Adriamycin, Alkeran, Ara-C,
  • BiCNU Busulfan
  • CCNU Carboplatinum, Cisplatinum, Cytoxan, Daunorubicin, DTIC, 5-FU, Fludarabine, Hydrea, Idarubicin, Ifosfamide, Methotrexate, Mithramycin, Mitomycin, Mitoxantrone, Nitrogen Mustard, Taxol (or other taxanes, such as docetaxel), Velban,
  • immunomodulators that can be used include AS-101 (Wyeth-1)
  • Another common treatment for some types of cancer is surgical treatment, for example surgical resection of a metastatic tumor.
  • surgical treatment for example surgical resection of a metastatic tumor.
  • radiotherapy for example administration of radioactive material or energy (such as external beam therapy) to the tumor site to help eradicate the tumor or shrink it prior to surgical resection.
  • Therapeutic agents for the treatment of AML are known in the art and can be administered in combination with any of the CD33-specific antibodies or antibody conjugates disclosed herein.
  • the subject is treated with an anti-leukemic therapeutic agent, such as cytarabine, idarubicin, etoposide, methotrexate or clofarabine.
  • the patient receives a hematopoietic stem cell transplant.
  • CD33 expression is detected in a biological sample.
  • the sample can be any sample, including, but not limited to, blood samples, tissue from biopsies, autopsies and pathology specimens. Biological samples also include sections of tissues, for example, frozen sections taken for histological purposes. Biological samples further include body fluids, such as blood, serum, plasma, sputum, spinal fluid or urine.
  • a biological sample is typically obtained from a mammal, such as a human or non-human primate.
  • a method of determining if a subject has a CD33-positive cancer by contacting a sample from the subject with a CD33-specific monoclonal antibody disclosed herein; and detecting binding of the antibody to the sample.
  • An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample identifies the subject as having a CD33-positive cancer.
  • a method of confirming a diagnosis of a CD33- positive cancer in a subject by contacting a sample from a subject diagnosed with a CD33- positive cancer with a CD33-specific monoclonal antibody disclosed herein; and detecting binding of the antibody to the sample.
  • An increase in binding of the antibody to the sample as compared to binding of the antibody to a control sample confirms the diagnosis of a CD33- positive cancer in the subject.
  • the monoclonal antibody is directly labeled.
  • the methods further include contacting a second antibody that specifically binds the monoclonal antibody with the sample; and detecting the binding of the second antibody.
  • An increase in binding of the second antibody to the sample as compared to binding of the second antibody to a control sample detects a CD33-positive cancer in the subject or confirms the diagnosis of a CD33-positive cancer in the subject.
  • the cancer is AML. In other cases, the cancer is a lymphoma or a squamous cell carcinoma.
  • control sample is a sample from a subject without cancer.
  • sample is a blood or tissue sample.
  • the antibody that binds (for example specifically binds) CD33 is directly labeled with a detectable label.
  • the antibody that binds (for example, specifically binds) CD33 (the first antibody) is unlabeled and a second antibody or other molecule that can bind the antibody that specifically binds CD33 is labeled.
  • a secondary antibody is chosen that is able to specifically bind the specific species and class of the first antibody. For example, if the first antibody is a human IgG, then the secondary antibody may be an anti-human-IgG.
  • Other molecules that can bind to antibodies include, without limitation, Protein A and Protein G, both of which are available commercially.
  • Suitable labels for the antibody or secondary antibody include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, magnetic agents and radioactive materials.
  • suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase.
  • suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin.
  • suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin.
  • a non-limiting exemplary luminescent material is luminol; a non-limiting exemplary a magnetic agent is gadolinium, and non-limiting exemplary radioactive labels include 125 I, 131 1, 5 S or H.
  • CD33 can be assayed in a biological sample by a competition immunoassay utilizing CD33 protein standards labeled with a detectable substance and an unlabeled antibody that specifically binds CD33.
  • a competition immunoassay utilizing CD33 protein standards labeled with a detectable substance and an unlabeled antibody that specifically binds CD33.
  • the biological sample, the labeled CD33 protein standards and the antibody that specifically bind CD33 are combined and the amount of labeled CD33 protein standard bound to the unlabeled antibody is determined.
  • the amount of CD33 in the biological sample is inversely proportional to the amount of labeled CD33 protein standard bound to the antibody that specifically binds CD33.
  • the antibody that specifically binds may be used to detect the production of CD33 in cells in cell culture.
  • the antibody can be used to detect the amount of CD33 in a biological sample, such as a tissue sample, or a blood or serum sample.
  • the CD33 is cell-surface CD33.
  • the CD33 protein is soluble (e.g. in a cell culture supernatant or in a body fluid sample, such as a blood or serum sample).
  • kits for detecting CD33 in a biological sample such as a blood sample or tissue sample.
  • a biological sample such as a blood sample or tissue sample.
  • a biopsy can be performed to obtain a tissue sample for histological examination.
  • Kits for detecting a polypeptide will typically comprise a monoclonal antibody that specifically binds CD33, such as any of the monoclonal antibodies disclosed herein.
  • the antibody is labeled (for example, with a fluorescent, radioactive, or an enzymatic label).
  • kits in one embodiment, includes instructional materials disclosing means of use of an antibody that binds CD33.
  • the instructional materials may be written, in an electronic form (such as a computer diskette or compact disk) or may be visual (such as video files).
  • the kits may also include additional components to facilitate the particular application for which the kit is designed.
  • the kit may additionally contain means of detecting a label (such as enzyme substrates for enzymatic labels, filter sets to detect fluorescent labels, appropriate secondary labels such as a secondary antibody, or the like).
  • the kits may additionally include buffers and other reagents routinely used for the practice of a particular method. Such kits and appropriate contents are well known to those of skill in the art.
  • the diagnostic kit comprises an immunoassay.
  • the details of the immunoassays may vary with the particular format employed, the method of detecting
  • CD33 in a biological sample generally includes the steps of contacting the biological sample with an antibody which specifically reacts, under immunologically reactive conditions, to CD33.
  • the antibody is allowed to specifically bind under immunologically reactive conditions to form an immune complex, and the presence of the immune complex (bound antibody) is detected directly or indirectly.
  • the antibodies disclosed herein can also be utilized in immunoassays, such as, but not limited to radioimmunoassays (RIAs), ELISA, or immunohistochemical assays.
  • the antibodies can also be used for fluorescence activated cell sorting (FACS).
  • FACS employs a plurality of color channels, low angle and obtuse light-scattering detection channels, and impedance channels, among other more sophisticated levels of detection, to separate or sort cells (see U.S. Patent No. 5,061,620). Any of the monoclonal antibodies that bind CD33, as disclosed herein, can be used in these assays.
  • the antibodies can be used in a conventional immunoassay, including, without limitation, an ELISA, an RIA, FACS, tissue immunohistochemistry, Western blot or immunoprecipitation.
  • This example describes the identification and characterization of six anti-CD33 monoclonal antibodies. Selection of human phage-displayed scFv and VH domain antibodies specific for CD33
  • a naive human scFv phage display library (approximate diversity, 1010 unique specificities), constructed from peripheral blood B cells of 50 healthy donors, and a human VH domain library were used for selection of scFvs or VH domains specific for recombinant human CD33.
  • Amplified libraries of 10 12 phage-displayed scFv or VH were incubated with 5, 3, and 1, ⁇ g of coated CD33 in a 5 x 100- ⁇ 1 volume, distributed equally in 5 wells of a 96-well plate for 2 hours at room temperature during the first, second and third rounds of biopanning, respectively.
  • the wells were washed 5 times for the first round and 10 times for the later rounds with phosphate-buffered saline containing 0.05% Tween 20 (PBST) to remove nonspecifically bound phage.
  • PBST phosphate-buffered saline containing 0.05% Tween 20
  • the bound phage were mixed with TGI competent cells for 1 hour at 37°C, and the phage were amplified from the infected cells and used in the next round of biopanning.
  • 380 clones were randomly picked from the infected TGI cells and each inoculated into 150 ⁇ 2YT medium containing 100 ⁇ g/ml carbenicillin and 0.2% glucose in 96-well plates using the automated BioRobotics BioPick colony picking system (Genomic Solutions, Ann Arbor, MI). After the bacterial cultures reached an optical density at 600 nm (OD600) of 0.5, helper phage M13K07 at a multiplicity of infection (MOI) of 10 and kanamycin at a final concentration of 50 ⁇ g/ml were added to the medium, and the plates were further incubated at 30°C overnight in a shaker at 250 rpm.
  • MOI multiplicity of infection
  • the phage supematants were mixed with 3% nonfat milk in PBS at a 4: 1 volume ratio and used for enzyme- linked immunosorbent assay (ELISA) to identify clones of phage displaying scFvs or VH domains with high CD33 binding affinity.
  • ELISA enzyme- linked immunosorbent assay
  • the supematants were incubated for 2 hours at room temperature with recombinant human CD33 coated at 50 ng per well in 96-well plates and washed five times with PBST (after overnight incubation at 4°C it was blocked with 3% nonfat milk in PBS and washed three times with PBS containing 0.05% Tween 20).
  • CD33-bound phage were detected using horseradish peroxidase (HRP)-conjugated goat anti-M13 antibody. After incubation with the antibody, the nonspecifically bound antibody was removed by washing wells, and the 3,3',5,5'-tetramethylbenzidine (TMB) substrate was added, and solution absorbance at 450 nm (A450) measured. Clones that bound to CD33 with A450 of >1.0 were selected for further characterization. Expression and purification of selected soluble ScFvs or VHs
  • VH and VL domains of the selected clones and the VH domain of the single-domain binders were DNA sequenced, and the scFvs or VH domains encoded by clones with unique sequences were expressed and purified as described below. Plasmids extracted from these clones were used for transformation of HB2151 cells. A single colony was picked from the plate containing freshly transformed cells, inoculated into 200 ml 2YT medium containing 100 ⁇ g/ml ampicillin and 0.2% glucose, and incubated at 37°C with shaking at 250 rpm.
  • FACS fluorescence activated cell sorting

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des anticorps monoclonaux humains qui se lient spécifiquement à CD33. L'invention concerne également des conjugués d'anticorps qui comprennent les anticorps monoclonaux spécifiques de CD33 (ou des fragments de liaison à l'antigène). L'invention concerne en outre des procédés de détection, de diagnostic et de traitement du cancer positif à CD33.
PCT/US2018/040257 2017-06-30 2018-06-29 Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation WO2019006280A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3066953A CA3066953A1 (fr) 2017-06-30 2018-06-29 Anticorps monoclonaux humains specifiques de cd33 et leurs procedes d'utilisation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762527165P 2017-06-30 2017-06-30
US62/527,165 2017-06-30

Publications (1)

Publication Number Publication Date
WO2019006280A1 true WO2019006280A1 (fr) 2019-01-03

Family

ID=62976328

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/040257 WO2019006280A1 (fr) 2017-06-30 2018-06-29 Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d'utilisation

Country Status (2)

Country Link
CA (1) CA3066953A1 (fr)
WO (1) WO2019006280A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227072A1 (fr) * 2019-05-04 2020-11-12 Inhibrx, Inc. Polypeptides de liaison à cd33 et leurs utilisations
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex
WO2023078968A1 (fr) 2021-11-03 2023-05-11 Affimed Gmbh Liants de cd16a bispécifiques
WO2024196877A1 (fr) * 2023-03-22 2024-09-26 University Of Florida Research Foundation, Incorporated Anticorps monoclonaux de lapin ciblant des antigènes de leucémie myéloïde aiguë

Citations (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4248870A (en) 1978-10-27 1981-02-03 Takeda Chemical Industries, Ltd. Maytansinoids and use
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4260608A (en) 1978-11-14 1981-04-07 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and methods of use thereof
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4308269A (en) 1979-06-11 1981-12-29 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
US4308268A (en) 1979-06-11 1981-12-29 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4317821A (en) 1979-06-08 1982-03-02 Takeda Chemical Industries, Ltd. Maytansinoids, their use and pharmaceutical compositions thereof
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5413797A (en) 1992-03-12 1995-05-09 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5512658A (en) 1990-05-11 1996-04-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5602095A (en) 1992-06-18 1997-02-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1999051643A1 (fr) 1998-04-03 1999-10-14 The Penn State Research Foundation Molecules chimeres mutagenisees a base d'il-13
US6884799B2 (en) 2003-03-31 2005-04-26 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof
WO2005052006A2 (fr) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticorps anti-cd22 et immunoconjugues mutes
US20060084162A1 (en) 2003-01-10 2006-04-20 Pradman Qasba Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
WO2007016150A2 (fr) 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Exotoxines de pseudomonas mutees a antigenicite reduite
US20070258986A1 (en) 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
WO2009016516A2 (fr) 2007-07-19 2009-02-05 Sanofi-Aventis Agents cytotoxiques comprenant de nouveaux dérivés de la tomaymycine et leur utilisation thérapeutique
US20090036431A1 (en) 2006-01-25 2009-02-05 Sanofi-Aventis Cytotoxic Agents Comprising New Tomaymycin Derivatives
WO2009032954A1 (fr) 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Délétions dans le domaine ii de l'exotoxine a de pseudomonas qui réduisent la toxicité non spécifique
US7511032B2 (en) 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
US7557099B2 (en) 2004-03-01 2009-07-07 Spirogen Limited Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
US20090304710A1 (en) 2006-10-19 2009-12-10 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
US20100047257A1 (en) 2006-07-18 2010-02-25 Sanofi-Aventis Antagonist antibody for the treatment of cancer
US20100203007A1 (en) 2009-02-05 2010-08-12 Immunogen Inc. Novel benzodiazepine derivatives
WO2011032022A1 (fr) 2009-09-11 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Exotoxine a pseudomonias améliorée à immunogénicité réduite
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
US20110268655A1 (en) 2007-05-11 2011-11-03 Joshua Goldstein Anti-alpha v immunoliposome compositions, methods and uses
US20130129753A1 (en) 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
WO2014052064A1 (fr) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps dirigés contre la mésothéline et procédés d'induction d'une activité anticancéreuse puissante
US20150099707A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Modified pseudomonas exotoxin a
WO2015089344A1 (fr) * 2013-12-13 2015-06-18 Genentech, Inc. Anticorps et immunoconjugués anti-cd33

Patent Citations (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4361650A (en) 1978-03-24 1982-11-30 Takeda Chemical Industries, Ltd. Fermentation process of preparing demethyl maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
US4248870A (en) 1978-10-27 1981-02-03 Takeda Chemical Industries, Ltd. Maytansinoids and use
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
US4260608A (en) 1978-11-14 1981-04-07 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and methods of use thereof
US4294757A (en) 1979-01-31 1981-10-13 Takeda Chemical Industries, Ltd 20-O-Acylmaytansinoids
US4322348A (en) 1979-06-05 1982-03-30 Takeda Chemical Industries, Ltd. Maytansinoids
US4317821A (en) 1979-06-08 1982-03-02 Takeda Chemical Industries, Ltd. Maytansinoids, their use and pharmaceutical compositions thereof
US4308269A (en) 1979-06-11 1981-12-29 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
US4308268A (en) 1979-06-11 1981-12-29 Takeda Chemical Industries, Ltd. Maytansinoids, pharmaceutical compositions thereof and method of use thereof
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
US4331598A (en) 1979-09-19 1982-05-25 Takeda Chemical Industries, Ltd. Maytansinoids
US4362663A (en) 1979-09-21 1982-12-07 Takeda Chemical Industries, Ltd. Maytansinoid compound
US4364866A (en) 1979-09-21 1982-12-21 Takeda Chemical Industries, Ltd. Maytansinoids
US4371533A (en) 1980-10-08 1983-02-01 Takeda Chemical Industries, Ltd. 4,5-Deoxymaytansinoids, their use and pharmaceutical compositions thereof
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4424219A (en) 1981-05-20 1984-01-03 Takeda Chemical Industries, Ltd. 9-Thiomaytansinoids and their pharmaceutical compositions and use
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4957735A (en) 1984-06-12 1990-09-18 The University Of Tennessee Research Corporation Target-sensitive immunoliposomes- preparation and characterization
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US5079163A (en) 1985-03-29 1992-01-07 Cetus Corporation Recombinant ricin toxin fragments
US4689401A (en) 1986-03-06 1987-08-25 Cetus Corporation Method of recovering microbially produced recombinant ricin toxin a chain
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4892827A (en) 1986-09-24 1990-01-09 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxins: construction of an active immunotoxin with low side effects
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
US5055303A (en) 1989-01-31 1991-10-08 Kv Pharmaceutical Company Solid controlled release bioadherent emulsions
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5271961A (en) 1989-11-06 1993-12-21 Alkermes Controlled Therapeutics, Inc. Method for producing protein microspheres
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5061620A (en) 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5506206A (en) 1990-04-23 1996-04-09 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
US5512658A (en) 1990-05-11 1996-04-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxins (PE) and conjugates thereof having lower animal toxicity with high cytocidal activity through substitution of positively charged amino acids
US5608039A (en) 1990-10-12 1997-03-04 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Single chain B3 antibody fusion proteins and their uses
US5254342A (en) 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
US5413797A (en) 1992-03-12 1995-05-09 Alkermes Controlled Therapeutics, Inc. Controlled release ACTH containing microspheres
US5854044A (en) 1992-06-18 1998-12-29 National Institutes Of Health Recombinant pseudomonas exotoxin with increased activity
US5602095A (en) 1992-06-18 1997-02-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5821238A (en) 1992-06-18 1998-10-13 The United States Of America As Represented By The Department Of Health And Human Services Recombinant pseudomonas exotoxin with increased activity
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US6124431A (en) 1993-10-01 2000-09-26 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5767237A (en) 1993-10-01 1998-06-16 Teikoku Hormone Mfg. Co., Ltd. Peptide derivatives
US5739116A (en) 1994-06-03 1998-04-14 American Cyanamid Company Enediyne derivatives useful for the synthesis of conjugates of methyltrithio antitumor agents
US5767285A (en) 1994-06-03 1998-06-16 American Cyanamid Company Linkers useful for the synthesis of conjugates of methyltrithio antitumor agents
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
WO1999051643A1 (fr) 1998-04-03 1999-10-14 The Penn State Research Foundation Molecules chimeres mutagenisees a base d'il-13
US7049311B1 (en) 1998-08-27 2006-05-23 Spirogen Limited Pyrrolbenzodiazepines
US7265105B2 (en) 1998-08-27 2007-09-04 Spirogen Limited Pyrrolobenzodiazepines
US7067511B2 (en) 1998-08-27 2006-06-27 Spirogen Limited Pyrrolobenzodiazepines
US20060084162A1 (en) 2003-01-10 2006-04-20 Pradman Qasba Catalytic domains of beta(1,4)-galactosyltransferase I having altered donor and acceptor specificities, domains that promote in vitro protein folding, and methods for their use
US6884799B2 (en) 2003-03-31 2005-04-26 Council Of Scientific And Industrial Research Non-cross-linking pyrrolo[2,1-c][1,4]benzodiazepines and process thereof
US7511032B2 (en) 2003-10-22 2009-03-31 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pyrrolobenzodiazepine derivatives, compositions comprising the same and methods related thereto
US20070258986A1 (en) 2003-11-19 2007-11-08 Govt of the US as represented by the secretary, Targeted Delivery System for Bioactive Agents
WO2005052006A2 (fr) 2003-11-25 2005-06-09 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Anticorps anti-cd22 et immunoconjugues mutes
US7557099B2 (en) 2004-03-01 2009-07-07 Spirogen Limited Pyrrolobenzodiazepines as key intermediates in the synthesis of dimeric cytotoxic pyrrolobenzodiazepines
US7528126B2 (en) 2004-03-09 2009-05-05 Spirogen Limited Pyrrolobenzodiazepines
WO2007016150A2 (fr) 2005-07-29 2007-02-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Exotoxines de pseudomonas mutees a antigenicite reduite
US20090036431A1 (en) 2006-01-25 2009-02-05 Sanofi-Aventis Cytotoxic Agents Comprising New Tomaymycin Derivatives
US20100047257A1 (en) 2006-07-18 2010-02-25 Sanofi-Aventis Antagonist antibody for the treatment of cancer
US20090304710A1 (en) 2006-10-19 2009-12-10 Sanofi-Aventis Novel anti-cd38 antibodies for the treatment of cancer
US20110268655A1 (en) 2007-05-11 2011-11-03 Joshua Goldstein Anti-alpha v immunoliposome compositions, methods and uses
WO2009016516A2 (fr) 2007-07-19 2009-02-05 Sanofi-Aventis Agents cytotoxiques comprenant de nouveaux dérivés de la tomaymycine et leur utilisation thérapeutique
WO2009032954A1 (fr) 2007-09-04 2009-03-12 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Délétions dans le domaine ii de l'exotoxine a de pseudomonas qui réduisent la toxicité non spécifique
US20100203007A1 (en) 2009-02-05 2010-08-12 Immunogen Inc. Novel benzodiazepine derivatives
WO2011032022A1 (fr) 2009-09-11 2011-03-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Exotoxine a pseudomonias améliorée à immunogénicité réduite
US20110256157A1 (en) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazepines and conjugates thereof
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
US20130129753A1 (en) 2011-11-17 2013-05-23 Pfizer Inc. Cytotoxic peptides and antibody drug conjugates thereof
WO2014052064A1 (fr) 2012-09-27 2014-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps dirigés contre la mésothéline et procédés d'induction d'une activité anticancéreuse puissante
US20150099707A1 (en) 2013-10-06 2015-04-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Modified pseudomonas exotoxin a
WO2015089344A1 (fr) * 2013-12-13 2015-06-18 Genentech, Inc. Anticorps et immunoconjugués anti-cd33

Non-Patent Citations (59)

* Cited by examiner, † Cited by third party
Title
"Harrison's Principles of Internal Medicine"
"Molecular Biology and Biotechnology: a Comprehensive DeskReference", 1995, VCH PUBLISHERS, INC.
"Oncology Pocket Guide to Chemotherapy", 1995, MOSBY-YEAR BOOK
"Remington's Pharmaceutical Science", 1995, MACK PUBLISHING COMPANY
"The Cancer Chemotherapy Handbook", 1993, MOSBY-YEAR BOOK
"The Encyclopedia of Molecular Biology", 1994, BLACKWELL SCIENCE LTD.
ABELOFF: "Clinical Oncology", 2000, CHURCHILL LIVINGSTONE, INC
AL-LAZIKANI ET AL., JMB, vol. 273, 1997, pages 927 - 948
ALTSCHUL ET AL., J MOL. BIOL., vol. 215, 1990, pages 403
ALTSCHUL ET AL., NATURE GENET., vol. 6, 1994, pages 119
BANDER, CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, vol. 10, no. 10, 2012, pages 3 - 7
BANGA, A.J.: "Processing, and Delivery Systems", 1995, TECHNOMIC PUBLISHING COMPANY, INC., article "Therapeutic Peptides and Proteins: Formulation"
BENJAMIN LEWIN: "Genes V", 1994, OXFORD UNIVERSITY PRESS
BETAGERI ET AL.: "Liposome Drug Delivery Systems", 1993, TECHNOMIC PUBLISHING CO., INC.
CHARI ET AL., CANCER RES, vol. 52, 1992, pages 127 - 131
CHOTHIA ET AL., NATURE, vol. 342, 1989, pages 877
CHOTHIA; LESK, JMOL BIOL, vol. 196, 1987, pages 901 - 917
CONNOR ET AL., PHARM THER, vol. 28, 1985, pages 341 - 365
CONNOR ET AL., PHARM. THER., vol. 28, 1985, pages 341 - 365
CORPET ET AL., NUCLEIC ACIDS RESEARCH, vol. 16, 1988, pages 10881
E.W. MARTIN: "Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING CO.
FAY; SCOTT, IMMUNOTHERAPY, vol. 3, no. 3, 2011, pages 381 - 394
FRANKEL ET AL., MOL. IMMUNOL., vol. 16, 1979, pages 101 - 106
GAUTAM BORTHAKUR: "Precision 're'arming of CD33 antibodies", 1 January 2013 (2013-01-01), XP055499788, Retrieved from the Internet <URL:http://www.bloodjournal.org/content/bloodjournal/122/8/1334.1.full.pdf?sso-checked=true> [retrieved on 20180814] *
GERRATANA, MED RES REV, vol. 32, no. 2, 2012, pages 254 - 293
GRANDI ET AL., CANCER TREAT REV, vol. 17, 1990, pages 133
HAMANN PHILIP R ET AL: "Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia", BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 13, no. 1, 1 January 2002 (2002-01-01), pages 47 - 58, XP009080679, ISSN: 1043-1802, DOI: 10.1021/BC010021Y *
HIGGINS; SHARP, CABIOS, vol. 5, 1989, pages 151
HIGGINS; SHARP, GENE, vol. 73, 1988, pages 237
HINMAN ET AL., CANCER RES, vol. 53, 1993, pages 3336 - 3342
IJNTEMA ET AL., INT. J. PHARM., vol. 112, 1994, pages 215 - 224
IMMORDINO ET AL., INT JNANOMEDICINE, vol. 1, no. 3, 2006, pages 297 - 315
JOHNSTON ET AL., PHARM. RES., vol. 9, 1992, pages 425 - 434
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KONDO ET AL., J BIOL. CHEM., vol. 263, 1988, pages 9470 - 9475
KREUTER, J.: "Colloidal Drug Delivery Systems", 1994, MARCEL DEKKER, INC., pages: 219 - 342
LANGER, ACCOUNTS CHEM. RES., vol. 26, 1993, pages 537 - 542
LEFRANC, NUCLEIC ACIDS RES, vol. 29, 2001, pages 207 - 9
LEIMGRUBER ET AL., JAM CHEM SOC, vol. 87, 1965, pages 5791 - 5793
LEIMGRUBER ET AL., JAM CHEM SOC, vol. 87, 1965, pages 5793 - 5795
LODE ET AL., CANCER RES, vol. 58, 1998, pages 2925 - 2928
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
ONDA ET AL., PROC NATL ACAD SCI USA, vol. 105, no. 32, 2008, pages 11311 - 11316
PAI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 88, 1991, pages 3358 - 3362
PASTAN ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1333, 1997, pages C1 - C6
PASZKO; SENGE, CURR MED CHEM, vol. 19, no. 31, 2012, pages 5239 - 5277
PEARSON; LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444
PEC ET AL., J. PARENT. SCI. TECH., vol. 44, no. 2, 1990, pages 58 - 65
PERRY ET AL.: "Chemotherapy"
PETTIT ET AL., ANTIMICROB AGENTS CHEMOTHER, vol. 42, 1998, pages 2961 - 2965
QASBA ET AL., BIOTECHNOL PROG, vol. 24, 2008, pages 520 - 526
QUINTIERI ET AL., CLIN CANCER RES, vol. 11, no. 4, 2005, pages 1608 - 1617
RIPAMONTI ET AL., BR J CANCER, vol. 65, 1992, pages 703 - 707
SIEGALL ET AL., J BIOL. CHEM., vol. 264, 1989, pages 14256 - 14261
SLAPAK; KUFE: "Principles of Cancer Therapy"
SMITH; WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
TICE; TABIBI: "Treatise on Controlled Drug Delivery", 1992, MARCEL DEKKER, INC., pages: 315 - 339
WELDON ET AL., BLOOD, vol. 113, no. 16, 2009, pages 3792 - 3800
WOYKE ET AL., ANTIMICROB AGENTS AND CHEMOTHER, vol. 45, no. 12, 2001, pages 3580 - 3584

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020227072A1 (fr) * 2019-05-04 2020-11-12 Inhibrx, Inc. Polypeptides de liaison à cd33 et leurs utilisations
CN114040927A (zh) * 2019-05-04 2022-02-11 印希比股份有限公司 结合cd33的多肽及其用途
US11560428B2 (en) 2019-05-04 2023-01-24 Inhibrx, Inc. CD33-binding polypeptides and uses thereof
JP7525510B2 (ja) 2019-05-04 2024-07-30 インヒブルクス インコーポレイテッド Ｃｄ３３結合性ポリペプチド及びその使用
US12084502B2 (en) 2019-05-04 2024-09-10 Inhibrx Biosciences, Inc. CD33-binding polypeptides and uses thereof
WO2022074206A1 (fr) 2020-10-08 2022-04-14 Affimed Gmbh Lieurs trispécifiques
WO2023007023A1 (fr) 2021-07-30 2023-02-02 Affimed Gmbh Corps duplex
WO2023078968A1 (fr) 2021-11-03 2023-05-11 Affimed Gmbh Liants de cd16a bispécifiques
WO2024196877A1 (fr) * 2023-03-22 2024-09-26 University Of Florida Research Foundation, Incorporated Anticorps monoclonaux de lapin ciblant des antigènes de leucémie myéloïde aiguë

Also Published As

Publication number Publication date
CA3066953A1 (fr) 2019-01-03

Similar Documents

Publication Publication Date Title
US20210324090A1 (en) Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use
US11939377B2 (en) Affinity matured CD22-specific monoclonal antibody and uses thereof
US12180296B2 (en) Cross species single domain antibodies targeting mesothelin for treating solid tumors
US10548987B2 (en) Antibody-drug conjugates for targeting CD56-positive tumors
US12012455B2 (en) Human monoclonal antibodies specific for FLT3 and uses thereof
AU2018268970B2 (en) Human monoclonal antibody targeting tnfr2 for cancer immunotherapy
WO2017196847A1 (fr) Anticorps anti-nouveau récepteur variable d&#39;antigène (vnar) et conjugués d&#39;anticorps ciblant des antigènes tumoraux et viraux
US12122843B2 (en) High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2017214182A1 (fr) Anticorps entièrement humain ciblant pdi pour l&#39;immunothérapie anticancéreuse
WO2019006280A1 (fr) Anticorps monoclonaux humains spécifiques de cd33 et leurs procédés d&#39;utilisation
WO2016022939A1 (fr) Anticorps monoclonaux humains spécifiques de 5t4 et leurs procédés d&#39;utilisation
WO2019005208A1 (fr) Anticorps de la mésothéline humaine et utilisations dans une thérapie anticancéreuse

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18743325

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3066953

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18743325

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载